PrecisionMed Exhibition & Summit Showguide 2022

24-25 MAY 2022 | CONRAD DUBAI

THE ONLY DEDICATED PRECISION MEDICINE EVENT IN THE MIDDLE EAST

SHOW GUIDE

precisionmedexpo.com PRECISIONMED EXHIBITION & SUMMIT 2022

1

The future of precision medicine, because everyone is different

Precision medicine

PrecisionMed Exhibition & Summit 2022 Conrad Hotel, Dubai. 24-25 May Join us at the upcoming PrecisionMed Exhibition & Summit 2022, taking place in Dubai from 24-25 May. You’ll hear from our key opinion leaders and customers across UAE through an interactive panel discussion, speak to our industry experts and experience a selection of the products and services we have to offer by visiting us at booth E05.

Speakers:

José Luis Costa

Dr. Shoiab al Zadjali

Global Director of Scientific Affairs, Clinical NGS and Oncology Division

Head of Research Laboratories

Thermo Fisher Scientific

Sultan Qaboos Comprehensive Cancer Care & Research Centre (SQCCCRC)

Dr. Susanna Akiki, PhD DipRCPath (UK) Consultant Clinical Scientist, Head of Haemato Oncology

Dr. Byoungkwon Kim M.D.

Dr. Shakir Bahzad

Consultant Pathologist

Clinical and Molecular Geneticist

Sheikh Khalifa Specialty Hospital

Hamad Medical Corporation

Find out more at thermofisher.com/precisionmed2022 For Research Use Only. Not for use in diagnostic procedures. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL34635 0422

Kuwait Medical Genetics Center

Sarah Chahine Emerging Markets Sales Leader Thermo Fisher Scientific

FOREWORD

I’m honoured to welcome you to our inaugural event, PrecisionMed Exhibition & Summit, and EMERGE GHI Investment Forum, the first event of its kind dedicated to drive advancements of precision medicine and healthtech in the Middle East, and the rest of the world.

I would like to thank His Highness Sheikh Nahyan Bin Mubarak Al Nahyan for his generous patronage. We have an exceptional line-up of thought-leaders, innovators and visionaries from around the globe, along with networking opportunities and a variety of panels and discussions covering a huge range of ground-breaking topics, research, and innovations.

PrecisionMed Exhibition is a platform established to nurture one of the most exciting areas of healthcare, and one that will prove vital to the future of human health. As we meet each year over the coming decade, we will be working together towards the implementation of precision medicine as standard practice – not just for major disease specialists, but for every physician in the region. Our community will share knowledge and expertise, inspire, and support each other in rolling out a vision for healthcare, which means every single patient receives the meticulously optimised treatment plan they deserve.

EMERGE GHI, meanwhile, is an opportunity for these innovations to be implemented at speed and at scale across the Gulf region. As an investment forum, this is where connections will be made that will change the trajectory of healthcare in the Middle East, and I’m thrilled that we are here to incubate the next generation of healthcare technology. We will also hear from both startups and bellwethers of the industry, who will be sharing their experience and wisdom about growing sustainable healthcare businesses that make an impact where it matters.

Lastly, I want to extend a huge thank you to our sponsors and partners for their support. I am humbled and inspired by the expertise and commitment we have been able to assemble here. Thank you for helping us build this community, and I look forward to meeting you over the course of the event.

Let’s together close the gap between patient care and research outcome.

David Stradling Event Director Co-located with

24-25 MAY 2022 CONRAD DUBAI

DOWNLOAD THE BRELLA APP AND NETWORK WITH INDUSTRY LEADERS.

Book Meetings

Browse Exhibitor & Products

View Speakers & Agenda

PRECISIONMED EXHIBITION & SUMMIT 2022

3

Our goal is to enable the analysis of anything, by anyone, anywhere.

Sequence short to ultra-long fragments of DNA/RNA, in real time, for rapid insights. Fully scalable devices to suit your needs — from pocket-sized to ultra-high throughput.

Find out more

visit • nanoporetech.com

follow • @nanopore

Oxford Nanopore Technologies, the Wheel icon, GridION, MinION and PromethION, are registered trademarks of Oxford Nanopore Technologies plc in various countries. 2022 Oxford Nanopore Technologies plc. All rights reserved.

Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

4 J000833_Advert_Black_Product_Corporate_Advert_Option 1_FAW.indd 1

25/03/2022 11:01

CONTENTS SHOW FORWORD

3

SPONSORS & PARTNERS

6

AGENDA

8

SPEAKERS

21

EXHIBITOR LIST

31

EXHIBITORS BY PRODUCT CATEGORY

35

EXHIBITOR PROFILES

39

INNOVATIONS AT THE SHOW

47

INDUSTRY ARTICLES

54

SHOW INFO DATES 24 - 25 May 2022 HOURS 8:00AM-5:30PM LOCATION Conrad Hotel, Dubai, UAE CONTACT hello@precisionmedexpo.com STAY UP TO DATE AND GET CONNECTED TO THE PRECISION MEDICINE INDUSTRY.

IMPORTANT NOTICE: We are committed to providing you with a safe environment following all the health & safety guidelines set out by the local authorities. PrecisionMed Exhibition & Summit will deliver the event with strict standards of health & safety precautionary measures, including social distancing, contactless transactions, and hygiene protocols.

INDEMNITY: Smart Planet Media Limited UK, UAE Logistics and VAT Partner: Pure Arabia, the organisers of the Precision Medicine Exhibition & Summit and Emerge GHI, accept no responsibility for the statements made in this catalogue, nor for any errors or omissions that may occur, however caused.

PRECISIONMED EXHIBITION & SUMMIT 2022

5

THANK YOU TO OUR SPONSORS YOU TO OUR SPONSORS AND THANK PARTNERS AND PARTNERS Organised By

smartplanetmedia Gold Sponsors

Strategic Partners

Silver Sponsors

6

THANK YOU TO OUR SPONSORS THANK YOU TO MEDIA PARTNERS AND PARTNERS AND SUPPORTERS

Travel Partner

Diamond Media Partner

Official Data Partner

Supporting Partner

Industry Partner

Headline Media Partners

Supported By

Collaboration Partner

Headline MediaPartners Partner Official Media

Headline Partner MediaMedia Partners

PRECISIONMED EXHIBITION & SUMMIT 2022

7

24 MAY D A Y 1

EMERGE GHI SUMMIT TIME

EMERGE GHI

8:00

08:00 - 09:00 Registration

8:15

MAIN STAGE

THE LAUNCHPAD

EMERGE CONCOURSE

The Launchpad

8:30 8:45 9:00

09:00 - 09:20 Welcome remarks on the PMES Stage

9:15 09:20 - 09:50 Keynote Presentation: The Way Forward - Leading Regional Figure to Discuss the Kind of Healthcare Problems That Need to Be Solved.

9:30 9:45

11:00

11:15

11:30

11:45

The Catalysts of Digital Health Tech Innovation in the Region

10:15

10:45

09:50 - 10:35 Panel Discussion: Global Demand for Digital Health Tech in the Midst of the Pandemic

10:00-10:20 Extracting Insights and Predicting Outcomes in Metabolic Disease

Triska Hamid, Moderator Omar Sati, Managing Partner, DASH Ventures Sacha Haider, Partner, Global Venture Capital Abdulkader Lamaa, Partner, McKinsey Roberto Ascione, CEO, Healthware International, Marco Mohwinckel, Chairman of the Board, Altibbi

Gendius, Rory Cameron, CRO & Co-Founder Mark Edge - Operations Manager

10:35 - 11:00 Coffee Break

10:30-10:50 Increasing Physician and Patient Participation in Clinical Trials by 10x Nexus, Petr Boiko, CEO Vadim Pinskiy - Co-Founder

11:00 - 11:45 Panel Discussion: Preconception Genetic Screening Through Whole Exome Sequencing: A Recommendation for the Arab Population:

11:00-11:20 The Future of Medicine MyEngene, Trent Marx, CEO & Chairman George Patrinos, Scientific Advisor

The Next Level of Innovation. How Is the Health-tech Space Evolving? Panel of Experts Discuss Global Industry Trends and How This Will Play Out in a Regional Context Triska Hamid, Moderator Sam Asgarian, CMO, Scipher Medicine Lana Ghanem, Managing Director, Hikma Ventures Javier de Echevarria Carreres, CEO, Veritas Genetics Intercontinental Edward Kliphuis, Partner, Sofinnova Partners Oliver Keown, Managing Director, Intuitive Ventures 11:45 - 12:15 Keynote: Digital Health - A Life Science Investments Perspective Simon Turner, Partner, Sofinnova Partners

8

Medjacket Private Ltd, Ram Karri, CEO

Ayman Sharaiha, Partner and Co-founder, Altibbi

10:00

10:30

09:30 - 09:50 Virtual Monitoring - Technology Advent

11:30-11:50 BioSapien, Khatija Ali

PRECISIONMED EXHIBITION & SUMMIT

MAIN STAGE

PMES

08:30 - 09:00 Registration 09:00 - 09:30 Official Opening

TECHNOLOGY SESSIONS

MEETING ROOMS

Technology Sessions

DOWNLOAD THE BRELLA MOBILE APP FOR THE LATEST AGENDA. AGENDA

09:30 - 10:00 Plenary Talk - Recording: Advancing Genomic Medicine Through Global Collaboration and Data Sharing Heidi Rehm, Chief Genomics Officer, Department of Medicine, MGH Co-Director, Medical and Population Genetics, Broad Institute Medical Director, Broad Institute Clinical Research Sequencing Platform Professor of Pathology, Harvard Medical School 10:00-10:20 Plenary Talk-The Path to Preventive Genomics Robert C. Green, MD, MPH,Professor of Medicine (Genetics), Broad Institute and Harvard Medical School

Breakthroughs in Genomic Science and Genomic Medicine

10:20-10:40 Enablers of Genomic Science for Precision Medicine.

Min S. Park, CSO, Sanimed International, Abu Dhabi 10:40-10:55 Genome Guided Therapy in Hemoglobinopathies and Neuropsychiatric Disorders George P Patrinos,Professor of Pharmacogenomics and Pharmaceutical Biotechnology, University of Patras 10:55-11:10 The Complete Picture of the Genome Rich Compton, General Manager, Oxford Nanopore Technologies Gulf Limited 11:10-11:25 Leveraging Scale and Technology to Advance Arab and Middle Eastern Genomics

11:00 - 11:45 It›s Getting Personal: Tumour Molecular Profiling with CancerPrescision & Co Stefan Griesbach, Head of Sales, CeGat

Dr. Younes Mokrab, Principle Investigator, Sidra Medicine 11:25-11:40 Clinical Pharmacogenomics Implementation: Challenges and Opportunities Mohamed Nagy, Head of Personalized Medication Management, CCHE 11:40-11:55 Improving the Practice of Healthcare using Predictive Genomics Today David Hanna, Director, Microarray Business Unit, Thermo Fisher Scientific 11:55-12:10 The Genomic Landscape of Rare Pediatric Disorders in the Middle East Ahmad Abou Tayoun, Director Genetic Laboratory, COE Genomics, Medical Affairs, Al Jalila Childrens Hospital

Download the Brella Mobile app to view the latest agenda and connect with health-tech experts PRECISIONMED EXHIBITION & SUMMIT 2022

9

24 MAY D A Y 1

EMERGE GHI SUMMIT

MAIN STAGE

THE LAUNCHPAD

EMERGE CONCOURSE

12:00

12:15

12:30

12:15- 13:15 Networking lunch

12:15- 13:15 Lunch Break

12:45

13:00 13:15 - 13:45 13:20 - 13:40 Keynote: From Zero to Hero: The Evolution of a Braingrade - An upgrade for the brain Health-tech Start-up Walking Through the Hurdles of New Modality Braingrade, Peter Schlecht, CEO & Co-Founder

13:30

13:45

14:00 14:15

Start-up and Grow - Changing the Consumer Healthcare Experience

13:15

Glen Tullman, Transcarent, CEO

13:45 - 14:15 Investment Space for Innovation and Digital Health.

From Sickcare to Healthcare – A Zoom into the European Healthtech Landscape

13:40 - 14:00 Azimov Lab Robot Dreams, Ulrich Weigelt, Managing Director CEO

Dr. Sarper Tanli, Diginova Health Solutions, Operating Partner Dr. Patrick Pfeffer, Aescuvest, CEO 14:15 - 14:45 Seasoned Entrepreneurs: Stories from the Trenches Edward Kliphuis, Sofinnova Partners - Moderator, Partner Javier de Echevarria Carreres, Veritas Genetics Intercontinental, CEO

14:10 - 14:30 Pakistan's First Integrated Virtual Healthcare Platform medIQ, Saira Siddique, CEO & Founder

14:30

14:45

14:45 - 15:15 Coffee Break

14:45 - 15:15 Coffee Break

15:15

15:30

10

Start-up and Grow in the GCC

15:00 15:15 - 16:00 Panel Discussion: Moderated by Triska Hamid: Opportunities in the Middle East for Innovators to Put Down Roots and to Flourish Through Favourable Business. Terms and Market Opportunity, Plug & Play?

Triska Hamid, Moderator Roberto Croci, Microsoft for Startups, Managing Director Ali Hashemi, GluCare, Co-Founder & Chairman

15:15 - 15:35 Leader Life Sciences Increasing the biorelevance of drug discovery with automated 3D cell cultureLeader Healthcare

15:35 - 15:55 SanoCRM, Firas Abdulwahed, Founder

MAIN STAGE

12:00-12:30 Keynote Speech:Thermo Fisher - Unleash the Value Local and Fast Molecular Profiling in Oncology Research Jose Luis Costa, Director Medical Affairs EMEA, Thermo Fisher Scientific 12:30 -1:30 Thermo Fisher Scientific Panel Discussion - The Use of Oncomine Solutions in Personalized Medicine and Research

Personalised Medical Advancements

Chair: Sarah Chahine, PhD, Emerging Markets Sales Leader, Clinical Sequencing Business, Thermo Fisher Scientific

TECHNOLOGY SESSIONS

MEETING ROOMS

12:00 - 12:45 A Blueprint for a Cure: From Single Cell Multi-omics to Precision Medicine Dr. Khalil Abou Elardat, Head of Application Support Department, Singleron Biotechnologies"

12:55 - 13:30 G42 Panel

Dr. Susanna Akiki, Consultant Clinical Scientist, Head of Haemato Oncology, Diagnostic Genomic Division, Hamad Medical Corporation, Doha, Qatar. Assistant Professor of Clinical Pathology & Laboratory Medicine , Weill Cornell Medicine, Qatar Dr. Byoung Kwon Kim, Consultant Pathologist, Department of Pathology, Sheikh Khalifa Specialty Hospital (SKSH) Dr. Shakir Bahzad, Head of Molecular Pathology Lab at Kuwait Cancer Control Center Dr. Shoaib al Zadjali, Head of Research Laboratories, Sultan Qaboos Comprehensive Cancer Care & Research Centre (SQCCCRC) 13:30 - 14:30 Lunch Break

13:30 - 14:00 Lunch Break

14:30-15:00 Keynote Speech-Leveraging Data from Individuals to Populations for Accelerated Drug Discovery and Development

New Trends in Precision Medicine in 2022

Howard Jacob, Vice President of Genomics Research and Head of Data Integration, AbbView

15:00-15:15 Machine intelligence-driven Precision Medicine: Are we there yet?

15:00 - 15:45 Omics Approach in Rare Disease and the Challenge of Small Numbers of Patients

Shameer Khader, PhD Senior Director of Advanced Analytics, Data Science, and Bioinformatics, AstraZeneca

Moderator: Raza Ahmed, Olink Proteomics

15:15-15:30 Precision Medicine and AI: Trends & Challenges Relevant to Patient-Centered Care Walid Qoronfleh, PhD, MBA, Executive Director, Q3CG Research Institute (QRI)

Dr Frank Schmidt, Associated Professor of Biochemistry and Director of the Proteomics Core of Weill Cornell Medicine in Qatar Dr Houari Abdesselem, Manager, Proteomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University Dr Stefan Nierkens, Medical Immunologist, Center for Translational Immunology, University Medical Center Utrecht 11 PRECISIONMED EXHIBITION & SUMMIT 2022

AGENDA

PRECISIONMED EXHIBITION & SUMMIT

24 MAY D A Y 1

EMERGE GHI SUMMIT

MAIN STAGE

THE LAUNCHPAD

16:00

16:15

16:30 16:45

12

Start-up and Grow in the GCC

15:45

16.00 - 17:00 16:00 - 17:00 DRAGON›S DEN: Gulf Edition: Growth-phase Dragon›s Den - Main Stage Health-tech Entrepreneurs Pitch Their Business Ideas to a Panel of Four Investors to See If They Can Crack the Nod., Jury Panel: Joe Stringer, Octopus Ventures, Principle Dr Mussaad M. Al-Razouki, Kuwait Life Sciences, Chief Investment & BDO Ashish Patel, Numis Tala Malhas, Global Ventures, Associate Marco Mohwinckel, Altibbi, Chairman of the Board Sophie Smith, NabtaHealth, Founder & CEO Growth Stage Finalists: Khatija Ali, BioSapien, CEO

EMERGE CONCOURSE

PRECISIONMED EXHIBITION & SUMMIT

MAIN STAGE

TECHNOLOGY SESSIONS

MEETING ROOMS

15:30-15:45 Diabetes Management in the Cloud: a Vastly Superior Hyper Personalized Novel Approach Combining Physical and Digital Ihsan Almarzooqi, Co-Founder and Managing Director, GluCare

Renyuan Luo (Louis), Vice President, BGI International Project Center and Marketing Director of Middle East and North Africa

15:55 - 16:40 Genetics-based Breast Cancer Personalized Prevention Programs in Europe Peeter Padrik, CEO & Founder, Antegenes

AGENDA

15:45-16:00 Making Precision Medicine Accessible to Everyone

Technological Innovations in Precision Medicine

16:00-16:20 MGI Tech - Leveraging MGI DNBSEQ Sequencing Technology in Precision Medicine and Personalized Genomics.

Toby Huang, Business Development Director, ME, MGI Tech 16:20-16:40 Leaders Life Sciences 16:40-17:00 Precision Health in the Qatar Foundation - Strategy and Achievements Prof. Richard O’Kennedy, B.Sc., Ph.D., C. Biol., FRSB., F.I.Biol.I., Dip. F.S., Dip. C.S., Dip. Computing, MRIA. Vice President of Research, Development, and Innovation at Qatar Foundation, Vice President for Research at HBKU. 17:00-17:20 Medical Grade Wearables for Patient Monitoring InHospital and at Home Dr James Mault, Founder and Chief Executive Officer, BioIntelliSense 17:20-17:40 Precision Medicine in Oncology: Liquid Biopsy.

Application and Challenges of Liquid Biopsy in Cancer Diagnostics and Monitoring Abdul Wahid Khan, Associate Vice President Healthcare, BIS Research 17:40-18:00 Cell and Gene Therapies from Lab to Clinic Dr Dzihan Abazovic, CEO, Vincula Biotech Group

Download the Brella Mobile app to view the latest agenda and connect with health-tech experts PRECISIONMED EXHIBITION & SUMMIT 2022

13

25 MAY D A Y 2

EMERGE GHI SUMMIT

TIME

EMERGE GHI

8:00

Registration

MAIN STAGE

THE LAUNCHPAD

EMERGE CONCOURSE

The Launchpad

8:15 8:30 8:45 9:00 9:15 09:35 - 09:50 The Emerging Healthtech Ecosystem: Enabling Factors for Innovation Success

9:45

Clare Roche, Manager, Health Policy & Insights, The Economist

10:00

10:15 10:30

10:45

Healthtech for Healthcare Infrastructure

9:30

11:00

09:40-10:00 Disrupting the Clinical Trials Landscape Integratize, Zahid Hussain, Digital Healthcare Consultant & Zakarya Mohammed, Global IT Analyst

09:50 - 10:20 State of Healthtech in the ME

10:00 - 10:20 Imaging Body Fat - Saving Lives

Yoram Wijngaarde, Founder, Dealroom.co

Adiposs, Andrej Babic, CEO & Co-Founder

10:20 - 10:50 Coffee Break

10:20 - 10:50 Coffee Break

10:50 - 11:15 The Future of Healthcare:The Re-imagination of Healthcare and Growth Opportunities in the New World Reenita Das, Partner, Senior Vice President, Healthcare and Life Sciences, Frost & Sullivan

11:15

11:15 - 11:30 Leader Healthcare Group

11:45

12:00

12:15

14

Digital Health-tech for Economic Efficiency

11:30

11:30 - 12.00 Investor Ask Me Anything

11:00 - 11:20 ScirosBio: A UAE Home Grown Biopharmaceutical Start-up for Treating Unmet Medical Needs ScirosBio (FZC), Madhu Subramani, Co-founder & CEO

Oliver Keown, Managing Director, Intuitive Ventures Lana Ghanem, Managing Director, Hikma Ventures Alasdair Thong, Founding Partner, Selvedge Venture/Mubadula Capital Edward Kliphuis, Partner, Sofinnova Partners Dr Mussaad M. Al-Razouki, Chief Investment & BDO, Kuwait Life Sciences

11:50 - 12:10 Adilson, Adil Achibane,

12:00 - 13:00 Lunch

12:00 - 13:00 Lunch

PRECISIONMED EXHIBITION & SUMMIT

MAIN STAGE

PMES

TECHNOLOGY SESSIONS

MEETING ROOMS

Technology Sessions

Registration

Dame Professor Sue Hill, NHS UK, Chief Scientific Officer for England 09:35-10:05 Keynote speech-Genomics Perspectives of Applied Personalized Health

09:35-10:20 Explore How 1-day NGS Can Help You Accelerate Your Lab Dr. Philips Jermann, Chief Molecular Biologist, Dr. Cristina Skrypnyk, Assistant Professor, Al-Jawhara University Hospital, Basel, Thermo Fisher Scientific Centre Dr Saba Habibollah, Dr Burhan Fakhurji, CEO and Funder, Cancer Cell and Molecular Biologist, Expert in Design and Operate Research Laboratory 10:05-10:25 Precision Molecular Diagnosis in Pediatrics

Regional Efforts in Precision and Genomic Medicine

Professor Ayman El-Hattab, Professor and Consultant Clinical Genetics 10:30-11:30 His Highness Sheikh Nahyan Bin Mubarak Al Nahyan, Cabinet Member and Minister of State for Tolerance of UAE & President of UAE Genetic Diseases Association

11:30-11:50 Mediclinic Precision Medicine James Steel, General Manager for Digital Transformation & Innovation, Mediclinic 11:50-12:10 Rare Diseases and Genomics

11:30 - 12:15 Breakthrough Cancer screening solution : A new paradigm in early cancer detection Dr Ramin Ajami, MD, MSC PGDip Oncology UK. President and founder of Lifegen Honorary Senior Associate specialist at Guy’s and St. Thomas’ Hospital London, Lifegen Health

Hinda Daggag, Corporate Genetic Project Head, SEHA

12:10-12:30 Preconception Genetic Screening Through Whole Exome Sequencing: A Recommendation for the Arab Population Lova Satyanarayana Matsa, Scientific Director, Igenomix

PRECISIONMED EXHIBITION & SUMMIT 2022

15

AGENDA

09:05-09:35 Plenary Talk - Genomics England and Precision Medicine

25 MAY D A Y 2

EMERGE GHI SUMMIT

MAIN STAGE

THE LAUNCHPAD

EMERGE CONCOURSE

12:30

12:45

13:00

13:15

13:30

13:45 14:00

14:15

13:00 - 13:45 Panel Discussion: Digital Medicine: Bigger Bang for your Buck Robert C Green, Moderator Simon Turner, Partner, SOFINNOVA Partners Dr. Burhan Fakhurji, CEO and Funder, Cancer Cell and Molecular Biologist, Expert in Design and Operate Research Laboratory Ahmed Awada, Snr. Manager, Virtual Health, Mediclinic Joanne Hackett, Head of Genomic and Precision Medicine, IQVIA Saif Aljaibeji, Chief Government Business Development Officer National Health Insurance CO 13:45 - 14:45 DRAGON›S DEN II - Gulf Edition: Early-stage health-tech entrepreneurs pitch their business ideas to a panel of four investors to see if they can crack the nod.

Early Stage Finalists Peter Schlecht, Founder & CEO, Braingrade Robert Green, MD, MPH, Co-Founder and Executive Chair, Nurture Genomics Ulrich Weigelt, CEO, RobotDreams Alexey Soshnin, Founder & CEO, Medixspace

14:45

14:45- 15:15 Coffee Break

15:15

15:30

15:45

16

Telebionix, Agjiath Chbib, COO, Founder

13:20-13:40 Prosperdtx Digital Health Platform Prosper Digital Therapeutics Inc, Lara Varjabedian, CCO

13:45-14:45 Dragon›s Den - Main Stage

Jury Panel Oliver Keown, Managing Director, Intuitive Simon Turner, Partner, SOFINNOVA Partners Alasdair Thong, Founding Partner, Selvedge Venture/Mubadula Capital Caroline Souchet, Venture Capital Investor, Crescent Enterprises

14:30

15:00

13:00-13:20 The Digital Health Revolution is in our Hands

14:55-15:15 Omnigene Medical Technologies Ltd., Claudine Grech Spiteri, Executive Director

15:15 - 15:45 Fireside chat - Digital Health Startups Weathering the VC Funding Storm: Insights from the Innovators Addressing Unmet Needs of Chronic Disease Patients Dr. Louiza Chitour, Snr. Program & Partnerships Manager-Health, Plug and Play Middle East, Moderator Ole-Bjorn Kolbaek, GM, GCC, Dawn Health Dr. Marcos Gallego Llorente, Snr. Consultant, Vintura Dr. David Kuraguntla, Founder and CEO, Alio 15:45-16:15 Temperatuure check: Key takeaways from EMERGE GHI and the countdown to EMERGE GHI 2023 Executive Summary of the Event and Strategic Initiatives for the Industry for the Year Ahead.

Triska Hamid, Moderator Edward Kliphuis, Partner, SOFINNOVA Yoram Wijngaarde, Founder, Dealroom Clare Roche, Manager, Health Policy & Insights , The Economist Abdulkader Lamaa, Partner, McKinsey

15:25-15:45 Non-invasive Glucometer “Edvais” Brain Beat, Edward Krizhanovsky, CEO Armen Grigorian, Co-founder

PRECISIONMED EXHIBITION & SUMMIT

MAIN STAGE

TECHNOLOGY SESSIONS

MEETING ROOMS

12:30-12:50 Implementation of Personalised Medicine in Qatar Salha Bujassoum, Hamad Medical Corporation 12:50-13:10 The Discovery of Novel Monogenic Forms of Inflammatory Bowel Disease Dr Bernice Lo, Principle Investigator, Sidra Medicine 13:10 - 13:25 UAE Post Covid PrecisionMed

13:25 - 14:00 Lunch

AGENDA

Aaron Han, Chief of Pathology, KCH Dubai

13:25 - 14:00 Lunch

14:00-14:25 Keynote Speech

14:00 - 14:45 Precision Medicine and the Transformation of Health Care in the Middle East H.E Dr Maryam Matar, Founder and Chairperson, UAE Dr. Samih Alqawlaq, Senior Clinical Sales Specialist, Genetic Diseases Association Illumina

Precision Medicine From Bench to Bed

14:25-14:45 Immune Precision Medicine in Cancers. Overview of a breakthrough innovation Dr Marjane Le Bagousse, Director, Medical & Market Development, Veracyte Immuno-Oncology 14:45-15:15 Keynote SpeechDr. Humaid Al Shamsi, President, Emirates Oncology Society 15:15-15:30 COVID-19: Lessons Learned from Precision Medicine and Autoimmunity Dr Houari Abdesselem, Manager, Proteomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation 15:30 - 16:00 G42 Presentation

*Agenda subject to change

15:20 - 16:05 Immune Precision Medicine in Cancers-Clinical Implications and Updated Scientific Data Dr Marjane Le Bagousse, Director, Medical & Market Development, Veracyte Immuno-Oncology, Veracyte

Download the Brella Mobile app to view the latest agenda and connect with health-tech experts PRECISIONMED EXHIBITION & SUMMIT 2022

17

Life en WORLD LEADING PRECISION ONCOLOGY

SCREENING

DIAGNOSIS

GUIDANCE

MONITORING

LifeGen is a UAE based business with the core mission of providing access to the leading solutions in screening, diagnosis, guidance and monitoring of cancer.

TRUCHECK A simple blood test that can enable early detection of multiple cancers in asymptomatic individuals. With 99,97% accuracy, Trucheck can detect the presence of more than 70 different types of tumours including: Breast Cancer, Colon Cancer and Prostate Cancer.

FDA

APPROVED WITH BREAKTHROUGH DESIGNATION

+50% 99.97%

INCREASE IN SURVIVAL RATE

ACCURACY IN DETECTING CANCER IN ASYMPTOMATIC INDIVIDUALS.

Join Us | Side Event

25th May - 12:00pm Breakthrough Cancer screening solution : A new paradigm in early cancer detection DR RAMIN AJAMI

MD, MSC PGDip Oncology UK. Founder & President of LifeGen Honorary Senior Associate specialist at Guy’s and St. Thomas’ Hospital London

RAMIN.AJAMI@LIFEGENHEALTH.COM EXCLUSIVE GCC PARTNER OF 18 WWW.LIFEGENHEALTH.COM

SILVER SPONSOR PRECISION MED EXPO 2022

Rare Diseases and Genomics

MAIN STAGE

16:00 - 16:15 Genome Sequencing & Preventive Medicine Joanne Hackett, Head of Genomic and Precision Medicine, IQVIA

TECHNOLOGY SESSIONS

MEETING ROOMS

16:15 - 17:00 How Twist Lead the Way in Personalised Medicine, Dr Vishal Dixit, Field Application Scientist,Twist Bioscience

16:15-16:30 Polygenic Risk Scores for Precision Prevention of Common Cancers Peeter Padrik, MD, PhD , CEO / Oncologist, Antegenes and Ass. Professor, University of Tartu, Estonia 16:30-16:45 Precision Medicine in the Clinic Prof. Fatma Al Jasmi, Chair of Genetic & Genomic Department, College of Medicine & Healthscience, UAE University, Al Ain

AGENDA

Precision Medicine From Bench to Bed

25 MAY D A Y 2

PRECISIONMED EXHIBITION & SUMMIT

16:45-17:10 The Qatari Mendelian Disease Program – Approaching Rare Diseases with Emerging Genomic Technologies at the Point of Care Dr Khalid Fakhro, Chief Research Officer and Director of the Precision Medicine Program, Sidra Medicine 17:10-17:25 Optimising outcome of CAR-T therapy in children with precursors B-ALL requires a personalised medicine approach Stefan Nierkens, Medical Immunologist, Center for Translational Immunology, University Medical Center Utrecht 17:25 - 17:40 Treasure of Life - Diseases treatable with Stem Cells Dr Fatima Al Hashimi, Director of Sheikh Zayed Genetic Research Centre

Download the Brella Mobile app to view the latest agenda and connect with health-tech experts

PRECISIONMED EXHIBITION & SUMMIT 2022

19

20

SPEAKERS

MEET GLOBAL KNOWLEDGE AND THOUGHT LEADERS

Dame Prof. Sue Hill

Dr. Samih Alqawlaq

Toby Huang, BSc, MSc

Dmitri Ossipov, PhD

Senior Clinical Sales Specialist, Illumina

BD Director, APAC & ME, MGI Tech Co Ltd

Head of Sales EMEA, CeGaT GmbH

Dr. Stefan Nierkens

Houari Abdesselem, PhD

Shoaib Al Zadjali, PhD

H.E Dr. Maryam Matar

Associate Professor and Medical Immunologist, Center for Translational Immunology, University Medica Center Utrecht

Manager, Proteomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University

Head of Research Laboratories, Sultan Qaboos Comprehensive Cancer Care & Research Centre (SQCCCRC)

Founder and Chairperson, UAE Genetic Diseases Association (UAEGDA)

Heidi Rehm, PhD

Dr Susanna Akiki, PhD DipRCPath (UK)

Byoungkwon Kim M.D.

George P. Patrinos

Consultant pathologist in Department of Pathology, Sheikh Khalifa Specialty Hospital (SKSH), United Arab Emirates

Professor, University of Patras, Greece

Chief Scientific Officer, England

Chief Genomics Officer, Department of Medicine, MGH Co-Director, Medical and Population Genetics, Broad Institute

Consultant Clinical Scientist, Head of Haemato Oncology, Diagnostic Genomic Division, Hamad Medical Corporation, Qatar

Adjunct Professor, United Arab Emirates University, Department of Genetics and Genomics, Al-Ain, UAE

PRECISIONMED EXHIBITION & SUMMIT 2022

21

Immunity assessed, Personalized treatment

IMMUNOSCORE® is included in Guidelines for Localized Colon Cancer

Help guide your therapy recommendations with precise information about patient immune response.

Designed to deliver critical information to help guide chemotherapy decision-making, IMMUNOSCORE® can be used in localized colon cancer to identify patients who may be spared adjuvant chemotherapy: In Stage II

In Stage III

70%

~of50% patients

of high-risk patients reclassified as low-risk

may be spared from longer chemotherapy

Pagès F et al. Ann Oncol. 2020

IMMUNOSCORE® in colon cancer is available as a CLIA or CE marked test to help guide oncologists’ day-to-day decisions.

22 Veracyte - Photograhy Adobe Copyright

SPEAKERS

SPEAKERS

Min S. Park, PhD

Hinda Daggag, PhD

Khalid Fakhro, PhD

Shameer Khader, PhD

CSO, Sanimed International, Abu Dhabi

Corporate Head of Genetic Projects, SEHA

Chief Research Officer, Sidra Medicine

Senior Director (Machine Learning Research), AstraZeneca

Marjane Le Bagousse, MD, MSc, EM

Dr. Shakir Bahzad, MD, FRCPC

Aaron Han, MD, PhD

José Luis Costa

Medical Director, Veracyte ImmunoOncology

Head of Molecular Pathology Lab, Kuwait Cancer Control Center

Consultant, Pathology, COVID Lab, Infection Control, King’s College Hospital London – UAE

Global Director of Scientific Affairs of the Clinical NGS and Oncology Division, Thermo Fisher Scientific

Ahmad Abou Tayoun, PhD, FACMG

Robert C. Green, MD, MPH

Peeter Padrik, MD, PhD

Director, Genomics Center at Al Jalila Children’s

Professor of Medicine, Harvard Medical School

Richard O Kennedy, B.Sc., Ph.D., C. Biol., FRSB., F.I.Biol.I., Dip. F.S., Dip. C.S., Dip. Computing, MRIA

Associate Professor of Genetics, Mohammed Bin Rashid University of Medicine and Health Sciences

Founder and CEO, Antegenes

Geneticist, Mass General Brigham, Broad Institute

Associate Professor, Oncology at University of Tartu, Estonia

Director, Genomes2People Research Program

Medical Oncologist, Tartu University Hospital, Estonia

Vice-President for Research, Hamad Bin Khalifa University Vice-President for Research, Development and Innovation (RDI), Qatar Foundation

PRECISIONMED EXHIBITION & SUMMIT 2022

23

Leader Life Sciences Presents, A Metaverse of Comprehensive Solutions for Precision Medicine Personalization has become a key in the 21st century, from the coffee we take to the apps we use –the theme of individuality is constant. Therefore, the demand for precision medicine is booming. From drug discovery to clinical trials to pharma to research and development to diagnostics, Leader Life Sciences explores a metaverse of comprehensive solutions that aims to disrupt the world of precision medicine.

.

.

.

24

SPEAKERS

SPEAKERS

Howard Jacob, PhD

Dr. Ihsan Almarzooqi

Vice President and Head of Genomic Research, AbbVie

Co-Founder & Managing Director, Glucare

Sarah Chahine

Ayman El-Hattab, MD

Emerging Markets Leader for Clinical Sequencing Division, Thermo Fisher Scientific

Consultant & Scientific Advisory Board member for Middle East, Igenomix

Lova Satyanarayana Matsa, PhD Diagnostic Director (WES, WGS), Igenomix

Carlos Buesa Arjol, PhD Founder and CEO, Oryzon

Mohamed Nagy, Pharm, RPh, MS

M. Walid Qoronfleh, PhD, MBA

Head of Personalized Medication Management Unit, Children’s Cancer Hospital, Egypt

Director of Healthcare Research and Policy, World Innovation Summit for Health (WISH)

PRECISIONMED EXHIBITION & SUMMIT 2022

25

Discover the world’s most promising health tech companies on health.dealroom.co

Dealroom is proud data partner for Emerge GHI

26

SPEAKERS

SPEAKERS

Rich Compton

Dr. Younes Mokrab

David Hanna

Renyuan Luo (Louis)

General Manager Oxford Nanopore Technologies Gulf Limited

Principle Investigator Sidra Medicine

Director Microarray Business Unit, Thermo Fisher Scientific

Vice President BGI International Project Center and Marketing Director of Middle East and North Africa

Dr James Mault

Dr Dzihan Abazovic

Founder and Chief Executive Officer, BioIntelliSense

Abdul Wahid Khan Associate Vice President - Healthcare, BIS Research

Dr Saba Habibollah Head of Education, Development and Quality Improvement Iranian Hospital

Fatma Al Jasmi, MBBS, FRCPC, FCCMG

Dr Burhan Fakhurji CEO & Founder, iGene

James Steel

Chair of Genetic & Genomic Department, College of Medicine & Health Science, UAE University

CEO, Vincula Biotech Group

General Manager for Digital Transformation & Innovation, Mediclinic

PRECISIONMED EXHIBITION & SUMMIT 2022

27

Co-located with

24-25 MAY 2022 CONRAD DUBAI

DOWNLOAD THE BRELLA APP AND NETWORK WITH INDUSTRY LEADERS.

Book Meetings

DOWNLOAD THE BRELLA APP

28

Browse Exhibitor & Products

View Speakers & Agenda

SPEAKERS

SPEAKERS

Stefan Griesbach Head of Sales CeGat

Dr. Philips Jermann Chief Molecular Biologist, University Hospital, Basel, T

Dr Bernice Lo

Dr Fatima Al Hashimi

Principle Investigator, Sidra Medicine

Joanne Hackett, Head of Genomic and Precision Medicine, IQVIA

Dr Ramin Ajami

Dr Vishal Dix

MD St. Thomas’ Hospital London, Lifegen Health

Field Application Scientist,Twist Bioscience

Dr Frank Schmidt, Associated Professor Qatar

Director Sheikh Zayed Genetic Research Centre

Prof.Humaid Al-Shamsi,MB(IRL),MRCP(UK),FRCP(Canada) ,FACP(USA), Director of Burjeel Cancer Institute, President Of Emirates Oncology Societya

PRECISIONMED EXHIBITION & SUMMIT 2022

29

Join our talk session: Leveraging MGI DNBSEQ Sequencing Technology in Precision Medicine and Personalized Genomics at PMES MAIN STAGE at 4:30 PM, 24th of May

30

EXHIBITOR LIST

PRECISIONMED EXHIBITION & SUMMIT 2022

31

A LEADING PROVIDER OF COMPLETE LABORATORY SOLUTIONS ACROSS THE MIDDLE EAST

SERVICE SUPPORT

32 marketing@gulf-scientific.com

TRAINING EXPERTISE

APPLICATIONS SUPPORT

gulf-scientific.com

Company

Stand Number

Country

Al Nawras Medi-Lab Supplies

B09

United Arab Emirates

Antegenes

D01A

Estonia

BGI

A01

China

BIS Research Inc.

D06

United States

CeGaT GmbH

A02B

Germany

Diginova Health Solution

B01B

United Arab Emirates

Forbes

D01B

United Arab Emirates

G42

A05

United Arab Emirates

Genetrics

B13

United Arab Emirates

Glutenvita

C09

Poland

Gulf Scientific Corporation

B16

United Arab Emirates

Igenomix

B03

United Arab Emirates

Illumina

B07

United Kingdom

Indus Health Plus

B01A

India

Integrated Gulf Biosystems

C06

United Arab Emirates

Invention Vision Medical Requisites Trading L.L.C

C11

United Arab Emirates

LaboShop

A04

United Arab Emirates

Leader Life Sciences

C01

United Arab Emirates

A03B

United Arab Emirates

MEDICLINIC

A03

United Arab Emirates

MGI

B10

China

Olink Proteomics

B15

Sweden

Omnigene Medical Technologies Ltd.

B14

Malta

Oxford Nanopore

B01

United Kingdom

Sengenics

C08

United States

SeqOne Genomics & Global Diagnostic Solutions

A02

France

Thermo Fisher Scientific

E05

United Kingdom

Veracyte

C10

France

LifeGen

PRECISIONMED EXHIBITION & SUMMIT 2022

33

EXHIBITORS LIST

EXHIBITORS LIST

We offer a wide range of clinical testing services Our services include innovative multiplex tests in the field of cancer diagnostics, cancer theranostics, autoimmune disease, dysbiosis, SARS-CoV-2 serology, and many more. Our strength is in innovation supported by xMAP technology (Luminex Corporation).

List of clinical tests: molecular classification of cancer.

Early Detection of cancer. autoimmune disease (CE-IVD) Dysbiosis (CE-IVD)

34

PRODUCT CATEGORY

PRECISIONMED EXHIBITION & SUMMIT 2022

35

EXHIBITORS BY PRODUCT CATEGORY Company

Stand Number

PRECISION ONCOLOGY

Company

Stand Number

Integrated Gulf Biosystems

C06

Antegenes

D01A

Leader Life Sciences

C01

BGI

A01

MGI

B10

BIS Research Inc.

D06

SeqOne Genomics & Global Diagnostic Solutions

A02

CeGaT GmbH

A02B

Thermo Fisher Scientific

E05

Diginova Health Solution

BO1B

MOLECULAR DIAGNOSTICS

Gulf Scientific Corporation

B16

Al Nawras Medi-Lab Supplies

B09

Igenomix

B03

Antegenes

D01A

Illumina

B07

BIS Research Inc.

D06

Integrated Gulf Biosystems

C06

CeGaT GmbH

A02B

Invention Vision Medical Requisites Trading L.L.C

C11

Diginova Health Solution

BO1B

Leader Life Sciences

C01

Igenomix

B03

LifeGen

A03B

Illumina

B07

Olink Proteomics

B15

Integrated Gulf Biosystems

C06

Sengenics

C08

Invention Vision Medical Requisites Trading L.L.C

C11

SeqOne Genomics & Global Diagnostic Solutions

A02

LaboShop

A04

Thermo Fisher Scientific

E05

Leader Life Sciences

C01

Veracyte

C10

Omnigene Medical Technologies Ltd.

B14

NEXT-GENERATION SEQUENCING (NGS)

Olink Proteomics

B15

Al Nawras Medi-Lab Supplies

B09

Sengenics

C08

BGI

A01

SeqOne Genomics & Global Diagnostic Solutions

A02

BIS Research Inc.

D06

DIGITAL HEALTH

CeGaT GmbH

A02B

Igenomix

B03

Illumina

B07

36

Al Nawras Medi-Lab Supplies

B09

BIS Research Inc.

D06

Diginova Health Solution

BO1B

Stand Number

Company

Stand Number

LaboShop

A04

Olink Proteomics

B15

Leader Life Sciences

C01

Omnigene Medical Technologies Ltd.

B14

Veracyte

C10

Sengenics

C08

Veracyte

C10

EPIGENETICS Al Nawras Medi-Lab Supplies

B09

PHARMACOGENOMICS (PGX)

BIS Research Inc.

D06

BIS Research Inc.

D06

CeGaT GmbH

A02B

CeGaT GmbH

A02B

Illumina

B07

Diginova Health Solution

BO1B

Integrated Gulf Biosystems

C06

Gulf Scientific Corporation

B16

Invention Vision Medical Requisites Trading L.L.C

C11

Indus Health Plus

B01A

Leader Life Sciences

C01

Invention Vision Medical Requisites Trading L.L.C

C11

Omnigene Medical Technologies Ltd.

B14

Leader Life Sciences

C01

Olink Proteomics

B15

AI & BIG DATA BIS Research Inc.

D06

SeqOne Genomics & Global Diagnostic Solutions

A02

Diginova Health Solution

BO1B

Thermo Fisher Scientific

E05

Leader Life Sciences

C01

Veracyte

C10

Olink Proteomics

B15

RARE AND ORPHAN DISEASE

SeqOne Genomics & Global Diagnostic Solutions

A02

BIS Research Inc.

D06

CeGaT GmbH

A02B

IMMUNOLOGY BIS Research Inc.

D06

Gulf Scientific Corporation

B16

CeGaT GmbH

A02B

Igenomix

B03

Gulf Scientific Corporation

B16

Illumina

B07

Illumina

B07

Olink Proteomics

B15

Integrated Gulf Biosystems

C06

SeqOne Genomics & Global Diagnostic Solutions

A02

Leader Life Sciences

C01

PRECISIONMED EXHIBITION & SUMMIT 2022

37

EXHIBITORS BY PRODUCT CATEGORY

Company

Genetic Analyses You Can Trust

CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications: Exome Diagnostics Tumor Diagnostics Research & Pharma Solutions Personalized Disease Prevention Founded in 2009 in Tübingen, Germany, the company combines state-of-the-art sequencing technology with medical expertise – with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumor analyses.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality. CeGaT‘s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO/IEC 17025 and thus meets the highest international standards.

Find out more: www.cegat.com CeGaT GmbH • Paul-Ehrlich-Str. 23 • 72076 Tübingen • Germany • +49 7071 565 44 55 • info@cegat.com

EXHIBITOR PROFILES PRECISIONMED EXHIBITION & SUMMIT 2022

39

EXHIBITOR PROFILE

AL NAWRAS MEDI-LAB SUPPLIES Stand Number: B09

United Arab Emirates https://www.alnawrasmls.com/ Al Nawras provides innovative solutions for its partners in the health care and life science research field.

Our vision is to develop the scientific and medical research to be able to integrate sustainability into the sector’s economy and business model.

Our mission is to provide innovative solutions for our clients in the health care and life science sector, with cooperation with our partners to offer technological advancements that help facilitate their work, whilst having a solid grasp of what they do.

Product Categories Digital Health Epigenetics Molecular Diagnostics Next-Generation Sequencing (NGS) Other

to common complex diseases (cancers, cardiovascular disease, diabetes, etc).

to science institutes, enterprises, medical facilities and healthcare organizations

Antegenes develops and implements advanced genetic tests based on polygenic risk scores technology to enable precision prevention. Antegenes has brought four innovative CE-marked genetic tests (in vitro medical devices, 98/79/EC) into clinical use. Our tests are for breast cancer, prostate cancer, colorectal cancer, and skin melanoma. Based on our tests we have created and implemented genetics-based precision prevention programs.

• works to advance technological innovation, reduce birth defects, fight tumors and protect against serious illness

We inform individuals and their doctors about their genetic disease risks and provide actionable medical recommendations that reduce the likelihood, severity and mortality of common cancers and other complex diseases.

Antegenes’ products are created scientifically with laboratory and clinical validity and clinical usefulness, which makes them usable in healthcare by a broad range of healthcare professionals and institutions. Products are based on peer-reviewed international research and have been evaluated and validated using anonymized population data of the UK Biobank and Estonian Biobank.

Our services include development and creation of genetics-based personalized cancer screening programs for different clinical settings and populations.

Product Categories Molecular Diagnostics Precision Oncology

ANTEGENES

Stand Number: D01A Estonia www.antegenes.com Antegenes® (est. 2018) is an ISO 13485 certified health-tech company and a registered healthcare services provider (laboratory services;medical genetics, oncology) in Estonia.

Antegenes is an international pioneer of precision preventive medicine, aiming to use personal genetic information to reduce the severity and mortality due

40

BGI

Stand Number: A01 China https://www.bgi.com/global A world leader in scientific and precision medicine services that: • provides leading research and precision medicine solutions

• promotes precision medicine to cure infections Product Categories Next-Generation Sequencing (NGS) Precision Oncology

BIS RESEARCH INC. Stand Number: D06 United States https://bisresearch.com/ BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

We offer syndicate as well as custom studies and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

Our BIS Healthcare division offers market intelligence for precision medicine, medical devices, digital health, life sciences, robotics and imaging, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 3 years, BIS Healthcare has published more than 70 reports

Product Categories AI & Big Data Chronic Disease Digital Health Drug Discovery Epigenetics Immunology Molecular Diagnostics Next-Generation Sequencing (NGS) Pharmacogenomics (PGX) Precision Oncology Rare and Orphan Disease Targeted Therapeutics Other

carried out in-house under scientific supervision.”

value chain to encourage stakeholder alignment.”

Product Categories

Product Categories

Epigenetics Immunology Molecular Diagnostics Next-Generation Sequencing (NGS) Pharmacogenomics (PGX) Precision Oncology Rare and Orphan Disease Targeted Therapeutics

AI & Big Data Chronic Disease Digital Health Molecular Diagnostics Pharmacogenomics (PGX) Precision Oncology Targeted Therapeutics Other

DIGINOVA HEALTH SOLUTION Stand Number: BO1B

United Arab Emirates

EXHIBITOR PROFILE

under the precision medicine banner. Additionally, BIS Research had been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform in 2019 and 2020.

G42 HEALTHCARE Stand Number: A05

United Arab Emirates https://www. g42healthcare.ar

https://www.diginovahealth.com

CEGAT GMBH

Stand Number: A02B Germany www.cegat.com CeGaT is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

Founded in 2009 in Tübingen, Germany, the company combines stateof-the-art sequencing technology with medical expertise - with the aim of identifying the genetic causes of diseases and supporting patient care. For researchers and pharmaceutical companies, CeGaT offers a broad portfolio of sequencing services and tumor analysis. CeGaT generates the data basis for clinical studies and medical innovations and drives science forward with its own insights.

The owner-managed company stands for independence, comprehensive personal customer service, and outstanding quality.

CeGaT‘s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO 17025, and thus meets the highest international standards. In order to obtain firstclass results, all processes are

Diginova Health Solutions, based in Dubai, empower proven and enterprise-ready digital health technologies by providing commercial and technical support, developing regional proof-ofconcept projects, and building essential partnerships. It provides services to international and regional companies to amplify the impact of their GCC expansion plans;presents the investors, who are eager to invest in digital health, with unique investment opportunities.

Diginova aims to improve outcomes by educating people on diseases before they become patients through the execution of digitally enabled solutions that move healthcare from the hospital into the home, helping vulnerable groups to live better life. The fastchanging healthcare environment is increasing the demand of advanced technology and innovative care models. It addresses the challenges facing the current healthcare system by working with its partners to implement winning strategies.

Diginova is dedicated to introducing change and adaptability in highly dynamic environments. It integrates different sectoral interests to build sustainable incentives for innovative service provisions, fostering collaboration across the healthcare

G42 Healthcare, a leading healthtech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalised and preventive care and transforming the traditional healthcare ecosystem.

At the forefront in the battle against

COVID-19, we established Biogenix Labs, the UAE’s first COVID-19 accredited large-scale throughput laboratory and facilitated the world’s first Phase III trials for an inactivated vaccine against COVID-19. The 4Humanity trials enrolled over 43,000 volunteers from 125+ nationalities across the pan-Arab region. Subsequently, we supported the UAE’s healthcare authorities implement a national vaccination drive. We continue to employ advanced AI techniques and vast computing resources to accelerate the detection of COVID-19 and conduct research into new vaccines and drug therapies.

Product Categories Precision Oncology Rare and Orphan Disease Chronic Disease Molecular Diagnostics AI & Big Data Next-Generation Sequencing (NGS) Digital Health Targeted Therapeutics

PRECISIONMED EXHIBITION & SUMMIT 2022

41

EXHIBITOR PROFILE

Stand Number: B13 United Arab Emirates www.genetricsinc.com

Genomics and Genetrics – Your

Trusted Partner in Personalized Molecular Diagnostics

Genetrics with more than 12 years of operations in UAE, is one of the fastest growing integrated Genomics Solution provider for both Molecular Diagnostics and Research customers in the Middle East in terms of Products and solutions.

Representing Cutting edge technologies from Personalized qPCR solutions, MLPA kits, NGS library Prep kits to Optical Genome Mapping for SVs and Large Indels that are not possible by other NGS technologies.

Genetrics skilled team of Product specialist, researchers, Bioinformatics and qualified Engineers can duly support our Genomic clients in terms of method development, Optimization, Training and service Support for their solutions matching to the factory standards.

Product Categories Precision Oncology Pharmacogenomics (PGX) Molecular Diagnostics Next-Generation Sequencing (NGS) AI & Big Data Immunology Epigenetics

GULF SCIENTIFIC CORPORATION Stand Number: B16

partnerships with market leaders that include, among others, Merck, PerkinElmer, Thermo Fisher Scientific’s Applied Biosystems, and Waters to ensure that clients have the best available resources to meet their critical laboratory needs.

With an unrivaled support structure that includes manufacturer-certified service and training centers, GSC is the preferred choice for companies in a wide range of industries including, clinical, pharmaceutical, food and beverage, oil and gas, environmental, and others.

In addition to a network of distinguished local agents, the GSC sales and service teams of over 200 professionals operates in various countries throughout the Middle East to ensure close reach to any laboratory.

Our Training Centre, which boasts three purpose-built laboratories and two lecture halls, provides firstrate facilities to train scientists and technicians from across the region.

Additionally, our headquarters in Dubai feature an extensive warehouse and operations hub that offers innovative logistics solutions for our partners and clients alike.

For over thirty years, Gulf Scientific Corporation has demonstrated its unwavering commitment to the development of the scientific community across the Middle East.

Product Categories Chronic Disease Drug Discovery Immunology Pharmacogenomics (PGX) Precision Oncology Rare and Orphan Disease Targeted Therapeutics

IGENOMIX

Stand Number: B03

United Arab Emirates

United Arab Emirates

https://gulf-scientific.com/

https://www.igenomix.net/

Founded in 1990, Gulf Scientific Corporation (GSC) is headquartered in Dubai, United Arab Emirates with four regional offices and a number of distribution outlets across the Middle East.

GSC has established strategic

42

A worldwide reference company in reproductive services and diagnostic genetic services.

Product Categories Molecular Diagnostics Next-Generation Sequencing (NGS) Precision Oncology Rare and Orphan Disease

ILLUMINA

Stand Number: B07 United Kingdom www.illumina.com For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. Our initial products enabled researchers to explore DNA in an entirely new way. Now, with more than 3400 patents worldwide and our sequencing-by-synthesis technologybeing used to generate over 90% of the world’s sequencing data, we are leading the way, one genomic breakthrough at a time.

While the rate of progress continues to accelerate exponentially as we move towards precision medicine, we have only just begun to discover the true impact of genomics in areas we touch, including oncology, reproductive health, genetic disease, agriculture, microbiology, and beyond. This realization, and the discoveries we know lie ahead, are what inspire us to push the boundaries of our imagination and drive innovation.

Product Categories Epigenetics Immunology Molecular Diagnostics Next-Generation Sequencing (NGS) Precision Oncology Rare and Orphan Disease Other

INDUS HEALTH PLUS Stand Number: B01A India www.indushealthplus.com Indus Health Plus has been trailblazing the Preventive Healthcare and Wellness industry since its inception in 2000. With the aim of making quality healthcare Available, Accessible and Affordable, Indus Health Plus has taken its services across the globe. Indus has a range of genetic products

Product Categories Pharmacogenomics (PGX)

INVENTION VISION MEDICAL REQUISITES TRADING L.L.C Stand Number: C11

United Arab Emirates www.ivision.com.co

INTEGRATED GULF BIOSYSTEMS Stand Number: C06

United Arab Emirates https://igbiosystems.com/ Integrated Gulf Biosystems (IGB) is a partner of choice for Life Science and Clinical Genomic Solutions in the Middle East (Kingdom of Saudi Arabia, United Arab Emirates, Qatar, Bahrain and Libya). Since its inception in 1999, IGB has differentiated itself through exemplary Support (Service and Application), Workflow solutions and good sales support. IGB are channel partners for Life Science giants such as Thermofisher Scientific, Hamilton (Robotics and Storage), Molecular Devices, and others. To provide Molecular and Genomic solutions for inherited and infectious disease diagnostics we feature validated clinical solutions from Fast-track Diagnostics, Premaitha Health, DNA Genotek, BAG Healthcare and Elucigene Diagnostic.

Product Categories Epigenetics Immunology Molecular Diagnostics Next-Generation Sequencing (NGS) Precision Oncologys

We are distributor company, based in Dubai. We represent Medical Diagnostic solutions and temperature control devices across the GCC market. We join hands with top class manufacturing companies across the globe, who represent very unique technology and solutions for medical, pharmaceutical, hospital and diagnostic industries across GCC countries.

Product Categories Epigenetics Molecular Diagnostics Pharmacogenomics (PGX) Precision Oncology

LABOSHOP

Stand Number: A04 United Arab Emirates www.laboshop.ae LaboShop is your go-to platform in MENA for everything related to molecular biology including tech products, premium services and news.

Product Categories Digital Health Molecular Diagnostics Other

LEADER LIFE SCIENCES Stand Number: C01

United Arab Emirates https://leaderlifesciences.com/ With more than a decade of excellence in the field of healthcare, medical sciences and education, Leader Healthcare Group incepted Leader Life Sciences in 2020 to serve the scientific community and facilitate breakthroughs by introducing innovative solutions and automation technologies across analytical sciences, biofabrication, animal research, histopathology, precision medicine, and OMICS. The impact-driven leadership team, headed by visionary Mr. Sukhdeep Sachdev, ensured the establishment of a knowledge-oriented culture that drives the team to achieve greatness and targeted milestones.

Leader Life Sciences holds immense pride to be established as a onestop scientific solution provider with exemplary services and products dedicated to playing a crucial part in contributing to healthy urban life with cutting-edge care. From drug discovery to clinical trials to pharma to research & development to diagnostics, explore a metaverse of comprehensive scientific solutions that aims to disrupt the world of precision medicine with Leader Life Sciences at Stand C-01. Visit us from May 24-25, 2022, at PrecisionMed Expo and Summit 2022 from 10 am to 5 pm.

Product Categories AI & Big Data Digital Health Drug Discovery Epigenetics Immunology Molecular Diagnostics Next-Generation Sequencing (NGS) Pharmacogenomics (PGX) Precision Oncology Targeted Therapeutics Other

PRECISIONMED EXHIBITION & SUMMIT 2022

43

EXHIBITOR PROFILE

under the brand - DNAwise;to give a complete analysis of your body type, health risks, and a recommended lifestyle.

EXHIBITOR PROFILE

LIFEGEN

Stand Number: A03B United Arab Emirates www.lifegenhealth.com At Lifegen, we proudly offer a multitude of innovative cancer solutions for screening, diagnosis, treatment guidance and follow up. Our cancer screening test, is the only FDA approved blood test for early screening and detection of Breast, Prostate and 70+ types of cancer which was granted the “Breakthrough” designation this year;A revolutionary test that soon will be a practice changer globally.

Product Categories Precision Oncology

MGI

Stand Number: B10 China https://en.mgi-tech.com/ MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and fulllife-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

As of December 31, 2020, MGI has 1,726 employees, and 32.79% of whom are R&D personnel. Founded in 2016, MGI operates in more than 70 countries and regions, serving more than 1000 customers. It has established scientific research and production bases, global training and service network in many

44

countries and regions around the world. MGI is one of the companies in the world that have the ability to independent develop and massproduce clinical high-throughput gene sequencers. Providing realtime, comprehensive, life long solutions, its vision is to lead life science innovation.

Product Categories Next-Generation Sequencing (NGS)

OMNIGENE MEDICAL TECHNOLOGIES LTD. Stand Number: B14 Malta genemt.com

OLINK PROTEOMICS Stand Number: B15 Sweden https://www.olink.com/ Olink offers an unmatched highmultiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.

Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia.

We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.

For more information, please visit www.olink.com Olink® is a registered trademark of Olink Proteomics AB. Product Categories AI & Big Data Chronic Disease Drug Discovery Immunology Pharmacogenomics (PGX) Precision Oncology Rare and Orphan Disease Targeted Therapeutics

Omnigene Medical Technologies Ltd. is actively engaged in innovations promoting accurate and precise tests from low volume and difficult samples. The tests can be used in the clinic for patient surveillance, and in research laboratories to measure multiple analytes in a low volume or highly degraded material.

The methodologies are versatile and can be used in various health areas, in research models, in archival material to minimise time lapse for validation of biomarkers, in liquid biopsies (circulating tumour cells and exosomes) and in clinical trials.

We developed tests and optimised services in the areas of cancer testing, autoimmune disease, inflammatory diseases, dysbiosis and neurological conditions.

The company also invests in development projects aimed to enhance existing technologies and to merge technologies towards specific aims. As a contract research organisation (CRO) we leverage our optimised methodologies to support the academic community and biotech companies to measure multiple analytes (DNA, RNA and proteins) in low-input and low quality material.

Omnigene Medical Technologies Ltd also represents companies that offer high-end technologies for the academic research laboratories and promotes cutting edge technologies for early detection of disease and its progression.

We specialise in emerging technologies, innovations, early detection of cancer, cancer progression, breast cancer, colorectal cancer, cervical cancer, lung cancer, gastric cancer, COVID-19 serology, vaccine surveillance, preclinical CRO, xMAP technology, multiplex assays, validation studies, liquid biopsies, exosome research, microbiome, and genetic services.

Chronic Disease Epigenetics Immunology Molecular Diagnostics

raw data to actionable results, The integrated genomic analysis solution delivers accurate results with increased efficiency and fast turnaround times Providing Diagnostics Solutions for: Rare and hereditary diseases, cancer predisposition, Somatic cancer diagnostics.

Product Categories

SENGENICS

Stand Number: C08 United States

AI & Big Data Molecular Diagnostics Next-Generation Sequencing (NGS) Pharmacogenomics (PGX) Precision Oncology Rare and Orphan Disease Targeted Therapeutics Other

www.sengenics.com Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, dataguided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

THERMO FISHER SCIENTIFIC Stand Number: E05

United Kingdom

Drug Discovery Immunology Molecular Diagnostics Precision Oncology Other

www.thermofisher.com

Stand Number: A02 France

https://seqone.com/ https://gds-eg.com/

Stand Number: C10 France https://io.veracyte.com/ Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases.

Our immuno-oncology diagnostic products and services are used to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Product Categories

SEQONE GENOMICS & GLOBAL DIAGNOSTIC SOLUTIONS

VERACYTE

Thermo Fisher Scientific is the world leader in serving science.

Customers worldwide trust our tools, services and solutions to help them accelerate innovation and enhance productivity. Together, we are making advancements that make a real difference.

We do that by providing an unmatched combination of innovative technologies, purchasing convenience, and comprehensive support through product and service brands that include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

The company provides a unique range of immune scoring solutions, including the Immunoscore® assay for assessing the immune contexture of a tumor.

Immunoscore® in colon cancer is available as a CLIA or CE marked test to guide day-today oncologists’ decisions.

Immunoscore® can be a diagnostic platform for many cancers, as immune response to tumor is a key hallmark of disease progression Product Categories Digital Health Immunology Precision Oncology

Our Mission is to enable our customers to make the world healthier, cleaner and safer.

Product Categories Next-Generation Sequencing (NGS) Precision Oncology Targeted Therapeutics

SeqONE Genomics is considered one of top leaders in Genetic data analysis and reporting in Europe and provide the shortest path from

PRECISIONMED EXHIBITION & SUMMIT 2022

45

EXHIBITOR PROFILE

Product Categories

46

INNOVATIONS AT THE SHOW PRECISIONMED EXHIBITION & SUMMIT 2022

47

INNOVATIONS AT THE SHOW

Explore the latest technologies driving efficiency in the healthcare industry.

AL NAWRAS MEDI-LAB SUPPLIES B09 Bio-Rad’s second-generation digital PCR system provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan Hydrolysis Probes. It offers unmatched sensitivity and precision for various applications.

The CFX Opus System is the next evolution in qPCR from Bio-Rad. With improved thermal performance and our proprietary, accurate optical shuttle system, your data will be more consistent than ever. A sleek, modern design includes a refreshed and easy-to-use interface with new connectivity options and features.

SEQONE GENOMICS & GLOBAL DIAGNOSTIC SOLUTIONS A02 Bioinformatics by SeqOne offers CE-IVD, HDS certified solutions from raw data to actionable highly customised report along with deep data analysis from end to end, starting from fastQ, VCF, BAM to comprehensive, customisable, actionable insights along with therapeutic and clinical trial recommendations.

THERMO FISHER SCIENTIFIC E05 BIS RESEARCH INC. D06 BIS Healthcare offers ground-breaking research and in-depth analysis on emerging trends in the precision medicine market. The market is segmented by product type, ecosystem, application, and region, highlighting value propositions and business models useful for industry leaders and stakeholders. BIS Research’s research reports also cover country-level analysis, go-to-market strategies of leading players and future industry opportunities.

48

Designed to make nextgeneration sequencing (NGS) accessible to clinical laboratories with all levels of sequencing expertise, the Ion Torrent Genexus Dx Integrated Sequencer from Thermo Fisher Scientific delivers an effortless user experience while enabling regulatory compliance.

It offers an easy and efficient workflow and a robust and flexible design for both diagnostics and research. interface with new connectivity options and features.

ANTEGENES D01A

DIGINOVA HEALTH SOLUTION B01B

MEDNAwise is a genetic solution in precision medicine from Indus Health Plus. MEDNAwise testing helps doctors to understand which drug suits best, manage treatment and increase its effectiveness.

MEDNAwise testing is based on pharmacogenomics, a study that uses your genetic information to predict your response to certain drugs/medicines, helping doctors prescribe safer and more effective medication.

AnteBC is a genetic test that assesses a woman’s personalised risk of developing breast cancer using a polygenic risk score (PRS).

It is designed to reduce the risk of premature mortality due to breast cancer through advanced breast cancer screening and other preventive measures. AnteBC is a registered CE-marked medical device (IVD).

ARC is a HIMSS stage 7 smart ICU which helps in preventing sepsis.

It presents a real-time view of the patient’s story using clinical surveillance and data visualisation to pro-actively identify risk and notify physicians. This state-ofthe-art ICU clinical information solution from Diginova Health Solution is the ultimate tool to manage ICU workflow efficiently and improve outcomes throughout the critical care unit.

GULF SCIENTIFIC CORPORATION B16

LIFEGEN A03B

The GeneTitan Multi-Channel Instrument automates array processing from target hybridisation to data generation by combining a hybridisation oven, fluidics processing, and state-of-the art imaging device into a single bench-top instrument. It provides a hands-free, automated solution for monitoring gene expression and genomewide SNP genotyping, bringing the highest throughput and laboratory productivity per technician.

Trucheck™ from LifeGen is a breakthrough FDA-approved non-invasive blood-based test that can detect multiple cancers at early stages in asymptomatic individuals with high accuracy, helping to save lives and preserve quality of life.

PRECISIONMED EXHIBITION & SUMMIT 2022

49

INNOVATIONS AT THE SHOW

INDUS HEALTH PLUS B01A

INNOVATIONS AT THE SHOW

BGI A01

BGI A01 COLOTECT™ is a non-invasive, highly sensitive screening test for colorectal cancer (CRC) and precancerous lesions. Human DNA is extracted from stool sample self-collected at home, and used for the multiplex methylation specific PCR to detect abnormal CRC gene markers - SDC2, ADHFE1, and PPP2R5C.

BGI’s NIFTY (non-invasive fetal trisomy test) is a safe and easy prenatal test for detecting fetal chromosomal abnormalities.

During pregnancy, cell-free fetal DNA circulates in the mother’s bloodstream. NIFTY requires taking >5mL of the mother’s peripheral blood to analyse cell-free fetal DNA. By using next-generation sequencing technology and bioinformatics analysis, it calculates the risk of chromosomal abnormalities.

OMNIGENE MEDICAL TECHNOLOGIES LTD. B14

CEGAT GMBH A02B

The SimpliPlex BC Amp Test identifies actionable gene amplifications in colorectal and breast cancer.

The RNA bead-based test uses xMAP technology (Luminex) and is accurate, sensitive and costeffective. The high-performance test can make use of low-quality and low-input samples, while its versatile technology offers non-invasive patient follow-up using liquid biopsies.

CancerPrecision® enables targeted treatment. At CeGaT, we have brought our tumor diagnostic tools to the next level. We aim to identify every possible therapeutically relevant change in a tumor. We have optimised target enrichment and complement by sequencing on NovaSeq6000, the latest and most reliable sequencing technology. With our interdisciplinary team, we uncover and interpret genetic variants responsible for tumor growth, drug resistance and treatment efficacy, and highlight potential pharmaceutical toxicity.

50

The Olink Signature Q100 is a benchtop system for protein biomarker analysis. It is a newly developed instrument for readouts of Olink® Target 96/48 and Olink® Focus protein biomarker panels. Previously, readout of these panels was exclusively carried out using the multi-functional Fluidigm® Biomark™ instrument. This dedicated solution enables researchers to run Olink kits more easily and conveniently in their own labs.

VERACTYE C10 Veractye’s Immunoscore® diagnostic technology improves patient care by answering important clinical questions throughout the patient journey in cancer and other diseases.

MGI B10 MGI’s DNBSEQ-G50 is a compact and flexible benchtop genetic sequencer. Its two different flow cells balance speed and affordability. FCS (Flow Cell Small) allows short turnaround time for short turnaround time (STAT) samples and FCL (Flow Cell Large) enables lower cost per sample.

DNBSEQ-G50 offers 3-4 read length options for both FCS and FCL, supporting a wide range of research and clinical applications.

Immunoscore® in colon cancer is available as a CLIA or CE marked test to guide day-to-day oncologists’ decisions. Immunoscore® can be a diagnostic platform for many cancers, as immune response to tumors is a key hallmark of disease progression.

SENGENICS C08 Sengenics can provide antibody profiling and neutralisation assays against multiple spike and nucleocapsid variants of the SARS-CoV-2 (COVID-19) virus, along with full-length and truncated cytokines. Our patented KREX® protein folding technology ensures only full-length, correctly folded proteins are analysed, resulting in highly specific and reproducible data.

Our ImmuSAFE Protein Array provides three different results: - Levels of antibody to the virus - Measurement of Ab neutralizing capability - Levels of autoantibodies to proteins

PRECISIONMED EXHIBITION & SUMMIT 2022

51

INNOVATIONS AT THE SHOW

OLINK PROTEOMICS B15

52

INNOVATIONS AT THE SHOW

INTEGRATED GULF BIOSYSTEMS C06 The Ion Torrent Genexus System automates sample and library preparation, sequencing, analysis, and reporting. The Genexus Purification System and Genexus Integrated Sequencer with Genexus Software work together seamlessly, tracking sample information and results automatically through the process.

INVENTION VISION MEDICAL REQUISITES TRADING L.L.C C11

LEADER LIFE SCIENCES C01 The epMotion 5075t is an automated liquid handling system that includes an integrated Eppendorf ThermoMixer® module to mix, heat or cool samples and reagents. The module can be loaded and unloaded with the gripper and pipetting to the mixer is possible before and after the mixing steps. The Eppendorf ThermoMixer module is fully software controlled, enabling pipetting onto other worktable positions while in operation.

At Invention Vision Medical Requisites Trading, we offer a complete range of qRT PCR based assays for the detection of key mutation hotspots in clinical oncology samples.

IGENOMIX B03 Genomic Precision Diagnostic GPDx (WES, CMA, MLPA, Sanger, expansion, Precision Panels)

PRECISIONMED EXHIBITION & SUMMIT 2022

53

Using genetic information to prolong lives Innovative genetic tests for early detection and prevention of cancer Antegenes is an ISO 13485-certified health tech company and medical laboratory founded in 2018 to make broad genetic information accessible for use in healthcare. It has developed innovative genetic tests for breast cancer (AnteBC), prostate cancer (AntePC), colorectal cancer (AnteCRC), and skin melanoma (AnteMEL). The tests, which assess an individual›s genetic risk of developing these cancers using a polygenic risk score (PRS) methodology, are intended to reduce the risk of premature cancer-related mortality through personalised precision screening and other preventive measures.

All tests are CE-marked in vitro diagnostic medical devices (IVD) for use at the clinical-grade level.

The tests provide answers to the following questions: • •

• •

•

What is a patient›s genetic risk level for specific cancer?

At what age and how should a patient start with specific screening?

Should a patient take additional measures to prevent cancer?

What can a patient do to reduce the risk of developing these specific cancers?

What changes and symptoms does a patient need to look out for concerning these specific cancers?

Antegenes’ tests provide risk-based personalised recommendations and follow-up actions to prevent or detect specific cancer at an early stage when it is still curable. As individual disease risks differ significantly, the prevention of cancer and other diseases must be far more precise and efficient than it currently is.

54

TEST DEVELOPMENT & METHODOLOGY The PRSs and their risk differentiation estimations were validated using anonymous data from the Estonian Biobank and UK Biobank. Based on large-scale genetic data, various risk prediction models published in the international scientific literature were compared, and the prediction accuracy of the best-performing models was evaluated on independent data (1-4).

The PRSs underlying the risk score tests (5-8) are tailored for practical use and independently validated (1-4). After validation, the risk score tests use 2,803 breast cancer-related SNPs, 121 prostate cancer-related SNPs, 91 colorectal cancer-related SNPs, and 28 melanoma-related SNPs to calculate personalised risk scores.

The genetic risk score tests serve to determine the carrier status of genetic variants that affect a patient›s individual risk. They are combined into polygenic risk assessments and the 10-year probability of developing the diseases.

Individual patient risk is put into context with the population background data and estimates about the genetic risks of individuals of the same sex, age, and nationality. Individual test results are accompanied by actionable follow-up recommendations. The final reports also contain information about clinical risk factors that are excluded from the polygenic risk estimations.

The tests are based on genome-wide association studies of primarily European ancestry but also have corrections for other ethnicities derived from analyses of risk performance with UK Biobank data on ethnic groups.

Antegens Team

References 1.

Tasa T, Puustusmaa M, Tõnisson N, Kolk B, Padrik P. Precision Breast Cancer

6.

EJ, et al. Association analyses of more than 140,000 men identify 63 new

Screening with a Polygenic Risk Score. medRxiv. 2020:2020.08.17.20176263 2.

Tasa T, Puustusmaa M, Tõnisson N, Kolk B, Padrik P. Precision Prostate Cancer Screening with a Polygenic Risk Score. medRxiv. 2020:2020.08.23.20180570.

3.

2020:2020.08.19.20177931.

4.

Tasa T, Puustusmaa M, Tõnisson N, Kolk B, Padrik P. Recommendations for Primary Prevention of Skin Melanoma. medRxiv. 2020:2020.08.25.20181610.

5.

prostate cancer susceptibility loci. Nature genetics. 2018;50(7):928-36.

7.

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic

Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nature

Tasa T, Puustusmaa M, Tõnisson N, Kolk B, Padrik P. Precision Colorectal Cancer Screening with Polygenic Risk Score. medRxiv.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders

genetics. 2019;51(1):76-87.

8.

Fritsche LG, Beesley LJ, VandeHaar P, Peng RB, Salvatore M, Zawistowski M, et al. Exploring various polygenic risk scores for skin cancer in the phenomes of the Michigan genomics initiative and the UK Biobank with a visual catalog: PRSWeb. PLoS Genet. 2019;15(6):e1008202.

Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104(1):21-34.

PRECISIONMED EXHIBITION & SUMMIT 2022

55

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function.

These systems are enabling studies that were not even imaginable just a few years ago, and moving us closer to the realization of personalized medicine. With rapid advances in technology taking place, it is mission-critical to offer solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service.

We strive to meet this challenge by placing a high value on collaborative interactions, rapid delivery of solutions, and meeting the needs of our customers.

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Illumina Office, Dubai, United Arab Emirates

56

Driving Progress in Genomics for All At Illumina, we’re making genomics more useful for all, for a better understanding of human health. By shining a brighter light on genomics, together we can harness the power to build a stronger world.

Empowering Bigger Breakthroughs From our earliest startup days, we’ve always aspired to transform human health. Each new product is designed to empower our community to explore DNA at an entirely new scale, and discover answers to life’s biggest questions. Like what causes a cancer cell to mutate? What’s the origin of a puzzling disease? Is it possible to prevent the next outbreak?

Or safeguard the world’s food supply? These challenges inspire us to push the boundaries of what’s possible, and connect more people to the technology and insights changing the world.

Making a Difference Now and In the Future Today we’re a global leader in genomics—an industry at the intersection of biology and technology. We’re passionate about helping our customers read and understand genetic variations through our increasingly accessible, simple solutions. The advances our solutions support are triggering a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. And we’ve only just begun.

PRECISIONMED EXHIBITION & SUMMIT 2022

57

MANAGE YOUR HEALTH THROUGH YOUR GENETIC PROFILE Precision Medicine is a personalised approach to healthcare in which an individual’s genetic profile is used to customise their health management plan, and which combines genetic information with family history, lifestyle and environmental factors, to ensure that the right treatment is delivered to the right person at the right time.

Our Genetic Testing Services include: • Non-Invasive Prenatal Testing (NIPT)

• Whole Exome

• Solid Tumour Profiling

• Preimplantation Genetic Testing

01

PATIENT CONSULTATION

02

SAMPLE DELIVERY

03

SAMPLE SEQUENCING

Patient affected by or at risk of suffering from a genetic disease.

Physician and patient discuss and agree upon suitable genetic tests

Patient samples along with signed documents sent to the precision medicine laboratory at a Mediclinic facility in the UAE

Patient samples are processed using state-of-the-art sequencing technology at our laboratory

04

05

06

AI-DRIVEN GENOMIC INTERPRETATION

Analyse the sequencing results and interpret complex genomic data using advanced AI technology

EXPERTISE YOU CAN TRUST. A MEDICLINIC INTERNATIONAL COMPANY. www.mediclinic.ae

58

FINAL PATIENT REPORT

Mediclinic Precise sends physician-ready clinical reports

PERSONALISED TREATMENT STRATEGY

The physician decides on the right treatment which best suits the patient

Precision medicine services for a better life

Customising health management through genetic profiles Mediclinic Precise is part of Mediclinic International, one of the world’s leading private healthcare companies with operations in Southern Africa, the United Arab Emirates, and Switzerland and a shareholding in Spire Healthcare in the UK. Mediclinic Precise has been developed to support the three divisions of Mediclinic International with precision medicine services to meet the current and future healthcare demands of patients.

In the UAE, all genetic testing is conducted using the latest sequencing technology at the specially commissioned CAP-accredited genetics laboratory at Mediclinic City Hospital in Dubai. The company’s multidisciplinary team of medical doctors, scientists, genetic counsellors, and molecular geneticists offers support to healthcare professionals responsible for patients affected by or at risk of a genetic disease.

Mediclinic Precise can work directly with patients and also provide guidance and support to healthcare personnel who may not be specialists in this area, thus enabling them to use the capabilities of these emerging technologies to personalise the management of genetic disorders, cancers, and other complex multifactorial disorders to the advantage of their patients.

The team at Mediclinic Middle East uses next-generation sequencing (NGS) technology as part of Mediclinic Precise’s programme to provide high-quality genetic testing. This involves an accurate and high-throughput sequencing service to support prenatal testing, cancer diagnosis, cardiac risk detection, and overall precision medicine. In conjunction with NGS technology, interpretation is performed utilising an AI-driven bioinformatics solution, which allows Mediclinic Precise to deliver a vast amount of essential data in support of the clinical diagnosis of many diseases, such as cancers and heart-related disorders. Together with its partners, Mediclinic Precise can utilise an AI approach to interpret exomes, targeted panels, and even whole genomes. This greatly improves the turnaround time for releasing clinical reports, enabling improved patient care and outcomes.

The company’s goal is to deliver effective, innovative, and high-quality precision medicine services at affordable prices for the purpose of enhancing lives in the UAE. With precision medicine, it aims to transform healthcare delivery in the region by interpreting genetic information to create personalised prevention and treatment plans for patients.

Mediclinic Precise believes that every patient is unique, so each health management plan should be, too. Through genomic testing, the company can target treatment to them and their DNA by taking into account their risk for certain genetic conditions and understanding how well they respond to particular medications and dosages.

Ultimately, Mediclinic Precise works to improve patients’ quality of life by providing them with the continuum of care across their diagnosis, genetic testing, and post-test journey.

PRECISIONMED EXHIBITION & SUMMIT 2022

59

60

The promise of proteomics Accelerating proteomics innovation to advance precision medicine Future healthcare will depend on a new generation of therapies, with development driven by a much deeper knowledge of the biology underlying human health and disease in combination with a precision medicine mindset to deliver the right treatment to the right patients at the right time. Proteomics, the comprehensive study of thousands upon thousands of proteins and their actions, is poised to be at the centre of this revolution.

Recent years have seen a clear trend towards a bigpicture, “systems biology” approach to biological questions, with studies that look at the multiple molecular and cellular aspects involved in the disease or process under investigation.

Following several decades of intense genomics research, new approaches are injecting vital insights into the dynamic biology underlying human health and disease.

These are exciting times for biomedical research and drug development given the start of a systematic analysis of all the building blocks that make up human beings.

As the most important class of biomolecules in the context of understanding real-time human biology, proteins should be at the centre of developing new, more efficient therapies that can be tailored toward individuals. This is due to some important features of proteins in general, including their role as executors of most biological processes (e.g., enzymes, cytokines, transcription factors), as dynamic indicators of phenotype in health and disease, and as the most actionable targets for therapeutic interventions (proteins are the targets of most current drugs).

PRECISIONMED EXHIBITION & SUMMIT 2022

61

High quality proteomics.

Unrivaled throughput.

Announcing Olink® Explore 3072 A significantly expanded high-throughput proteomics platform, offering uncompromised data quality with coverage of all major biological pathways.

Announcing Olink® Signature Q100 A benchtop system for protein biomarker analysis, developed specifically for Olink Target and Focus protein biomarker panels.

Olink Proteomics www.olink.com enquires@olink.com

62

OVERCOMING TECHNOLOGICAL LIMITATIONS

While the vital role of proteins in understanding human biology was recognised many decades ago, technological limitations severely restricted the comprehensive investigation of the huge number of proteins that could be important in various biological processes and diseases. Proteins are far more complex to investigate than, for example, DNA, and technologies to detect or measure them have suffered from a number of key issues. These include lack of specificity of detection (particularly in multiplex assay formats), poor sensitivity, narrow dynamic range, low throughput, and large sample volume requirements. Such issues have especially restricted large-scale discovery studies aimed at examining a broad range of proteins in vast numbers of human samples.

This situation is changing fast, however, and Olink’s PEA technology for protein biomarker discovery overcomes all of the technical limitations that have slowed the impact of proteomics. With Olink, scientists can now use only a few microlitres of blood to simultaneously measure thousands of human proteins with highly specific, thoroughly validated assays that cover an enormous dynamic range (fg/mL to µg/mL). For example, the Olink Explore 3072 platform with NGS readout can analyse 4,600 samples per week to measure approximately 3,000 proteins using one NGS instrument, generating around 14 million protein data points.

Olink’s vision is to accelerate proteomics together with the drug development and research communities to achieve the goal of precision medicine and individualised healthcare based on a deep understanding of realtime human biology. The company’s game-changing technology is a significant step in realising that goal, but it is only by working closely with the scientific community that this vision can be advanced.

Collaboration and sharing are at the heart of scientific progress, and Olink is thrilled to witness the creation of customer-driven partnerships dedicated to these principles across a growing range of therapeutic areas. International consortia such as SCALLOP, CORAL, and COLLIBRI are sharing and combining their Olinkgenerated protein data from multiple cohorts to greatly increase the statistical power of their studies and rapidly gain key insights to accelerate progress. Olink applauds and supports these initiatives, deeming a collaborative approach to be a key factor in helping proteomics achieve its objectives.

of proteomics in delivering new and better therapies.

The company also sees the rapidly growing importance of protein biomarker programmes across the drug discovery and development process and will continue to work closely with the industry to maximise the impact

Olink will increasingly stand at the hub connecting basic and clinical research with drug development, continually creating new protein biomarker solutions that can accelerate the implementation of new biological insights into better outcomes for tomorrow’s patients. The company is committed to helping achieve its vision of a new era of precision medicine based on a proteomics-driven, deep understanding of human biology. It will support such efforts through constantly improving its portfolio of world-class proteomic solutions and making them more readily accessible to a wider audience, facilitating open collaboration and data sharing among the research community and the pharmaceutical industry, and providing cutting-edge tools for biostatistical analysis and bioinformatics to help transform increasingly large and complex datasets into actionable insights and biological understanding.

PRECISIONMED EXHIBITION & SUMMIT 2022

63

A multidisciplinary approach to solving clinical needs

CREATING INNOVATIVE MULTIPLEX ASSAYS FOR PERSONALISED TREATMENT Omnigene Medical Technologies Ltd. is actively engaged in innovations promoting accurate and precise tests from lowvolume and difficult samples. The tests can be used in the clinic for patient surveillance and in research laboratories to measure multiple analytes in a low-volume or highly degraded material. The methodologies are versatile and can be applied in various health areas, research models, archival material (to minimise time lapse for biomarker validation), liquid biopsies (circulating tumour cells and exosomes), and clinical trials. Omnigene has developed tests and optimised services for cancer testing, autoimmune disease, inflammatory diseases, dysbiosis, and neurological conditions.

The company also invests in development projects seeking to enhance existing technologies or merge technologies towards specific aims. As a contract research organisation (CRO), it leverages its optimised methodologies to support the academic community and biotech companies in measuring multiple analytes (DNA, RNA, and proteins) in low-input and low-quality material.

The innovative multiplex assays (SimpliPlex) are RNA bead-based assays that measure the expression of multiple tumour-associated biomarkers in low abundance samples. These methodologies have been optimised for multiplex digitalised readouts using various sample sources, from archival formalin-fixed paraffin-embedded (FFPE) tissues to blood-derived exosomes.

WORKFLOW OF THE SIMPLIPLEX ASSAY The SimpliPlex RNA-bead plex assays utilise the Quantigene branched DNA technology that runs on the Luminex xMAP technology. Paramagnetic microspheres (beads) are internally infused with specific portions of red and infrared fluorophores and measured by the Luminex optics (red laser/detector) to identify the beads known to harbour probes specific to the analytes. The Quantigene branched DNA technology builds a molecular scaffold on the specifically bound probe-target complex to amplify the signal read by a green laser/LED. The assay workflow includes a pre-analytical phase involving the lysis/homogenisation of the input material and an analytical phase encompassing hybridisation, pre-amplification, and signal amplification with a total hands-on time of two hours. Multiplexing allows the measurement of 40 analytes on the MAGPIX CE-IVD instrument.

64

PERFORMANCE OF THE SIMPLIPLEX ASSAY Gene expression can be measured using Omnigene’s RNA-based multiplex assays that are sensitive enough to quantify heterogeneity in FFPE tissue using stained microdissected material. In comparison with the reference methods using snap-frozen and FFPE tissues derived from patient and xenograft samples, the bead-based multiplex assays outperformed the qRT-PCR when using FFPE tissuederived RNA, giving reliability coefficients of 99.3%-100% versus 82.4%-95% for qPCR results.

Multiplexing provides both sensitivity and versatility in biomarker validation, and in Omnigene’s hands, it has become instrumental in measuring RNA transcripts in cells at low abundance, mimicking the isolation of circulating tumour cells from blood. In addition, the simple workflow with direct measurement using lysed cells allows this assay to translate more efficiently to clinical settings.

In conclusion, the innovative multiplex assays enable precise and personalised treatment, taking into account the heterogeneity of primary tumours, tumour progression during therapy, and the metastatic surveillance of the individual patient. The versatility of the method allows the development of various assays to support different applications. Omnigene’s first innovative methods were developed for the molecular classification of luminal and basal breast cancer and the prediction of sensitivity to a specific therapy in the triple-negative breast cancer subtype.

Currently, the company is developing colorectal cancer assays for the early detection of metastatic disease, the detection of circulating tumour cells (CTCs) that have a mesenchymal origin, and patient management, utilising its expertise in measuring biomarkers in plasm-derived exosomes. The multiplex assays have a wide range of possible applications in the diagnosis of tumours and their surveillance during therapy.

Among the main advantages of these methods is the implementation of high throughput analysis, which has a positive impact on remote testing, and the utilisation of such assays in patient surveillance and clinical trials.

Another benefit is that the digitalised result excludes subjectivity and equivocal interpretation, which are common events in image-based measurements, and also eliminates the need for highly specialised facilities and human resources.

In addition, they allow the accurate and precise detection of multiple targets in one assay, thus minimising the use of precious patient samples, and enable the measurement of gene expression in heterogeneous tumours and lowinput/low-quality patient material.

The method is streamlined with current pathology laboratory practices, resulting in a workflow that is costeffective and has minimal turnaround time.

PRECISIONMED EXHIBITION & SUMMIT 2022

65

Unleashing the Power of Autoantibodies to Advance Precision Medicine

Driving discovery of next-gen biomarkers with novel seromics technologies and services Autoantibody biomarker discovery Autoantibody biomarkers for predicting adverse events Autoantibody biomarkers for drug response prediction Autoantibody biomarkers for Dx and CDx development Sengenics patented KREX® protein folding technology ensures specific and reproducible capture of autoantibodies from patient samples allowing you to discover new biomarkers and establish signatures for patient stratification, treatment response prediction and diagnostic development.

Ready to accelerate your biomarker program?

Contact us at enquiries@sengenics.com

www.sengenics.com 66

Seromics technologies for next-gen biomarker discovery ADVANCING PRECISION MEDICINE THROUGH THE POWER OF AUTOANTIBODIES

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Its solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction, and companion diagnostics development.

The company’s novel seromics technologies drive the creation of protein microarray services and products for autoantibody biomarker profiling. Its focus is on helping advance the discovery, validation, and use of biomarkers in the fields of autoimmune disease, immuno-oncology, neurological conditions, and infectious disease.

Founded in 2008, Sengenics was built on technology developed at Cambridge University.

Its KREX® technology ensures that the proteins on its arrays are correctly folded, of full length, and functional. This is critical for autoantibody discovery because over 90% of antibodies recognise the shape of an epitope, not the amino acid sequence.

Sengenics works with many of companies as well as biopharma, research organisations, and 160 companies and institutions advance their research and THE ONLY CORRECTLY FOLDED, FULL-LENGTH, FUNCTIONAL PROTEIN ARRAY TECHNOLOGY The patented KREX® protein-folding technology accelerates the discovery of autoantibody biomarkers by enabling the expression of functional proteins to create high-density arrays. It provides a simple and rapid way to immobilise and purify correctly folded proteins for the detection of autoantibodies.

• • •

•

KREX® ensures that only correctly folded proteins are immobilised on the array surface.

Misfolded proteins are prevented from attaching and are washed away.

Immobilised proteins retain their folded structure, behaving as if they are in free solution on the hydrogel-coated array surface.

This ensures each assay is run on correctly folded, full-length, functional proteins, which is crucial for autoantibody-based assays where more than 90% of antibodies recognise conformational epitopes that are only available if the protein is correctly folded.

COMPETITIVE ADVANTAGES Due to Sengenics’ protein folding and array manufacturing technology:

the world’s top pharmaceutical academic institutions, contract disease foundations. More than have used its platform to biomarker development.

• • •

Autoantibody binding to the proteins on its arrays is highly specific, with a high signal-to-noise ratio.

It offers picomolar sensitivity, so only small amounts of sample are required (~10μl).

Its inter- and intra-array reproducibility are exceptional.

The company’s experienced team will help partners design and run their studies. Its bioinformatics experts can assist with analysis, while its protein scientists can collaborate on creating a custom array to meet specific needs.

KEY APPLICATIONS Autoantibody biomarkers identified and validated using Sengenics protein arrays have shown utility in a range of high-value applications, from early disease detection and patient stratification to treatment monitoring and prediction of treatment outcomes and immune-related adverse events (irAE).

• • • •

Biomarker discovery Patient stratification Response and adverse event prediction Diagnostics and CDx development PRECISIONMED EXHIBITION & SUMMIT 2022

67

Veracyte’s Immunoscore Test: Guiding Care in the Era of Precision Oncology and Personalized Treatment At Veracyte, our mission is to answer important questions to help inform better diagnosis and treatment decisions for patients in cancer and other diseases. Our immunooncology diagnostic products and services are used to help guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Within immuno-oncology, we are particularly focused on colon cancer, where our Immunoscore® assay assesses the immune contexture of a tumor and the ability of the patient’s individual immune system to fight tumor cells.

Colon cancer is a major global public health problem with an urgent need to refine diagnosis and treatment. After a patient undergoes colon cancer surgery, an important next step is to determine whether or not they should receive chemotherapy. Throughout this treatment decisionmaking process, oncologists evaluate various clinical pathological prognostic factors. However, traditional risk classification for colon cancer is not optimal – some patients are undertreated, while others are exposed to unnecessary toxicity associated with chemotherapy.

Today, tools and technologies are available that can help physicians better assess a patient’s immune

Figure 2: Assessing patient’s immune response to cancer based on lymphocytic infiltration evaluation within the microenvironment of the tumor.

68

Figure 1: Relative contribution of each risk parameter to survival. Immunoscore adds resolution to traditional risk assessment tools.

response to cancer, providing actionable insights into the microenvironment of the tumor and how it interacts with the body’s physiology. Among these novel technologies is Veracyte’s Immunoscore colon cancer test, a powerful tool that adds a new dimension of insight into colon cancer and helps guide treatment decisions by evaluating how efficiently a patient’s immune system is fighting the tumor.

Dr. Jérôme Galon, the inventor of the Immunoscore assay, pioneered the idea that the immune cells that surround the cancer are equally as important as the genetic mutations of cancer cells in determining how quickly the disease may proliferate within a patient. In 2021, Dr. Galon received the prestigious Prix Galien award in recognition of his groundbreaking research, which was the basis for the development of the Immunoscore test.

By providing a robust, precise, and quantitative assessment of lymphocytic infiltration in human tumors, Immunoscore gives healthcare providers insight into the risk of relapse. A low Immunoscore means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, a high Immunoscore means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

Figure 4: Immunoscore in Stage II T4N0 untreated patients (n=132) from the International SITC study*. A high Immunoscore (IS High) indicates a lower risk of relapse. Conversely, a low Immunoscore (IS Low) indicates a high risk of relapse.

The Immunoscore test is supported by more than 15 years of research involving 6,500+ patients. In an international clinical study published in The Lancet assessing the clinical utility of the Immunoscore, the test proved to be a powerful and independent prognostic indicator of patient survival.i The test’s utility was further validated when it was included in major industry guidelines, including the ESMO Clinical Practice Guidelines for Diagnosis, Treatment and follow-up of Patients with Localised Colon Cancer in 2020 and the Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis Treatment and Follow-up of Patients with Localised Colon Cancer in 2021. , Additionally, the World Health Organization (WHO) cited immune response as an essential and desirable diagnostic criterion for colorectal cancer, in addition to traditional histological parameters in its latest edition of the Digestive System Tumours. * The Immunoscore is currently indicated for localized colon cancer, however, since immune response at the tumor is a key hallmark of disease progression, we believe this robust technology has potential as a diagnostic tool for many other cancers. With its focus on cutting-edge technologies in precision oncology, Veracyte is excited to expand our Immunoscore offerings into the Middle East. Please note that Veracyte delivers the Immunoscore results from its CLIA laboratories, and that it might be considered for Research Use Only in some markets, please contact your local distributors for confirmation. If you are interested in learning more about the Immunoscore colon cancer test, please fill out our contact form and a Middle East representative will be in touch. *The World Health Organization is not endorsing the Immunoscore® commercial assay.

References i.

Pagès F et al. The Lancet 2018

ii.

Galon J, Hermitte F, Mlecnik B, et al., J Clin Oncol.2020; 38.15 (suppl; abstr 4105)

iii.

Argilés G et al. Annals of Oncology 2020

iv.

Yoshino T et al. Annals of Oncology 2021

v.

WHO Classification of Tumours Editorial Board. Digestive System Tumours 2019

PRECISIONMED EXHIBITION & SUMMIT 2022

69

MALE TOILET

CAFE MEETING AREA

LUNCH AND NETWORKING AREA

FLOOR PLAN ENTRANCE

A 02

GLOBAL DIAGNOSTICS SOLUTIONS

B 04

INDUS

BGI

B 05

B 08

B 01 A 02B

OXFORD NANOPORE

CeGat

B 09 P4ML

AL NAWRAS

B 07

B 03

B 10

ILLUMINA

IGENOMIX

B 01B

MGI

DIGINOVA

B 13

MEDICLINIC LifeGen

LEADER LIFE SCIENCES

A 04

B 15 OLINK

GENETRICS

C 01

A 03B

A 03

B 14

D 01A

B 16

OMNIGENE

ANTEGENES

GULF SCIENTIFIC CORP

C 06

FORBES

A 05 G42

C 05

PMES HOUSE STAND

THERMO FISHER SCIENTIFIC

C 08

C 09

GLUTENVITA

BY HOLIST

SENGENICS ENTRANCE

TO CONFERENCE MAIN ENTRANCE

COFFEE BREAK

D 05

E 05

INTEGRATED GULF BIOSYSTEMS

D 02

D 01B

LABOSHOP

2

B 11

COFFEE AREA

VISITOR REGISTRATION

FEMALE TOILET

EMERGING INNOVATOR PODS

B 01A

A 01

D 07

D 06

BIS RESEARCH

C 10

C 11

IVISION

VERACYTE EXIT

MEDIA STAND

24-25 MAY 2022 | CONRAD DUBAI

HEALTH-TECH INNOVATORS AND INVESTORS LEVERAGING TECHNOLOGY TO DRIVE EFFICIENCY AND CUT COST IN HEALTHCARE

SHOW GUIDE

emergeghi.com EMERGE GHI 2022

1

CONTENTS Sponsors & Partners

5

Speakers

6

Industry report

10

Mobile app

12

Launchpad - Health-tech innovators hub

13

Healthcare Revolutionaries

18

IMPORTANT NOTICE: We are committed to providing you with a safe environment following all the health & safety guidelines set out by the local authorities. Emerge GHI will deliver the event with strict standards of health & safety precautionary measures, including social distancing, contactless transactions, and hygiene protocols.

INDEMNITY: Smart Planet Media Limited UK, UAE Logistics and VAT Partner: Pure Arabia, the organisers of the Precision Medicine Exhibition & Summit and Emerge GHI, accept no responsibility for the statements made in this catalogue, nor for any errors or omissions that may occur, however caused.

EMERGE GHI 2022

3

Connect to a deeper source of genomic data interpretation

www.seqone.com

SeqOne offers a seamless path from raw data to actionable insights: Oncology & inherited diseases Variant prioritisation Therapeutic recommendations Custom reports CE-IVD

To find out more about SeqOne's integrated genomics analysis solution visit us on booth A02 or contact our Regional Distributor GDS

+966 58 189 84 97 4

info@gds-eg.com

www.gds-eg.com

Travel Partner

Diamond Media Partner

Official Data Partner

Headline Media Partners

SPONSORS & PARTNERS

THANK YOU TO OUR SPONSORS AND PARTNERS Supported By

Industry Partner

Collaboration Partner

Headline MediaPartners Partner Official Media

Headline Partner MediaMedia Partners

EMERGE GHI 2022

5

SPEAKERS SPEAKERS Tala Malhas

Dudi Klein

Sacha Haider

Ross Walker

Associate, Global Ventures

Co Founder & Managing Partner, Alive VC

Partner, Global Ventures

Head of Strategy, Cigna Middle East & Africa

Mussaad Al Razouki

Tushar Singhvi

Clara Roche

Roberto Croci

Chief Investment & BDO, Kuwait Life Sciences Company

Deputy CEO & Head of Investments, Crescent Enterprises

Manager – Health Policy & Insights, Economist Impact

Managing Director, Microsoft for Startups Middle East & Africa

Marco Mohwinckel

Abdulkader Lamaa

Yoram Wijngaarde

Alexander Hoffmann

Independent Director and Chairman of the Board, Altibbi

Partner, McKinsey Digital Labs

Founder and CEO, Dealroom.co

Managing Partner, Kingstone Schweizer Ventures

Eckhardt Weber

Doron Dinstein

Sean Slovenski

Corey McCann

Managing Partner, Heal Capital

Venture Partner, Entrée Capital

Chief Executive Officer, BioIQ

President and CEO, Pear Therapeutics

6

SPEAKERS

SPEAKERS

Jalil Allabadi

Dr. Sarper Tanli

Edward Kliphuis

Oliver Keown, MD

Co-Founder, Altibbi

CEO, Diginova Health Solutions Ltd

Partner, Sofinnova Partners

Director, Intuitive Ventures

Lana Y. Ghanem

Alasdair Thong

Sophie Smith

Amal Enan

Managing Director, Hikma Ventures

Founding Partner, Selvedge Venture

Founder and CEO, Nabta Health

Managing Partner, Lotus Capital

Omar J. Sati

Mohanad Fors

Roberto Ascione

Ali Hashemi

Managing Partner, DASH Ventures

Global Head of Digital, Almirall

CEO, Healthware Group

Co-Founder & Chairman, Glucare

Javier de Echevarria

Eddie Martucci

Glen Tullman

Prem Tumkosit

CEO, Veritas Intercontinental

Co-Founder and CEO, Akili Interactive Labs

Chief Executive Officer, Transcarent

MD, Merck Global Health Innovation Fund

EMERGE GHI 2022

7

WHO WE ARE Illumina is an applied genomics technology company making genomics useful for all.

We are tirelessly working to create the leading-edge technology that enables clinicians and researchers to not only understand the genome but also fully tap its power.

Discoveries that were unimaginable just a few years ago are becoming routine, and we’re just getting started.

FAST FACTS

FOUNDED IN

NUMBER OF EMPLOYEES

ANNUAL REVENUE (2020)1

ACTIVE SEQUENCING SYSTEMS INSTALLED

1998

>7,800

$3,236M USD

17,000

HEADQUARTERS

San Diego, California USA

COUNTRIES SERVED

PRESIDENT & CEO

115

Francis deSouza

SEQUENCING SYSTEMS Next-generation sequencing (NGS) is revolutionizing research, enabling experiments that weren’t possible before.

Illumina offers a range of innovative NGS platforms that deliver exceptional data quality and accuracy, at a massive scale.

NovaSeqTM 6000

NextSeqTM 550Dx*

NextSeqTM 2000

MiSeqTM and MiSeq Dx*

Production-Scale Sequencers

MiniSeqTM

iSeqTM100

Benchtop Sequencers

For Research Use Only. Not for use in diagnostic procedures. *For In Vitro Diagnostic Use

APPLICATIONS • • • •

Oncology Agriculture Genetic Disease Infectious Disease

8

CUSTOMERS • Microbial Genomics • Reproductive Health • Molecular & Cell Biology

• • • •

Clinics Hospitals Research Labs Healthcare Systems

• Academic Institutions • Government Agencies • Pharmaceutical Companies

MAKING BREAKTHROUGHS POSSIBLE At Illumina, we’re amidst the most important human health transformation of our time, as sequencing delivers new insights into the genome. We’ve made great strides in the field of genomics, and we’re just getting started. From diagnosing disease in critically ill infants to developing new treatments for cancer: Illumina is helping to improve human health by unlocking the power of the genome.

Cost of Sequencing, per Human Whole Genome 2001 2020

$100 million2 $6003

Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million per human genome to less than $600 USD today.

WHERE WE OPERATE United States

San Diego *Headquarters Foster City Hayward Baltimore Madison

Brazil

Germany Berlin

Netherlands Eindhoven

China

Sao Paulo

Bejing Shanghai

United Kingdom

Japan

Cambridge

France Evry

Tokyo

Osaka

Singapore

South Korea Seoul

Australia

Melbourne

CORPORATE SOCIAL RESPONSIBILITY

OUR RECOGNITION

As a global corporate citizen, Illumina is committed to deepening our impact on human health by serving as a champion for patients, the community, and our planet.

FACILITIES • • • • •

Green Building Design Reduce CO2 Emissions Increase Renewable Energy Reduce Water Footprint Reduce Waste to Landfill

PRODUCT • Design for Environment • Packaging & Dry Ice Reduction SUPPLY CHAIN • Supplier Commitments • Supplier Diversity

2030 TARGETS

90% Diversion of landfill waste at all main campuses4

75% Reduction in packaging

20% Diverse supplier spend

Glassdoor Best Place to Work (2019) Forbes’ World’s Best Employers (2019)

1 Preliminary 2020 Annual Revenue 2 Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: www.genome.gov/sequencingcosts 3 NovaSeq™ 6000 Sequencing System 4 Main campus locations currently include: San Diego, Foster City, Hayward, UK Illumina Centre, Netherlands, Singapore Woodlands

EMERGE GHI 2022

9

DEALROOM REPORT

The State of Healthtech in the MENA region Update for

April 2022 The remarkable growth of the Middle East and North Africa region’s (MENA) healthcare sector over the previous decade, fueled by both public and private finance, has firmly established regional healthcare as a worldwide player. In 2020-2021, the Medical Tourism Index indicated that Dubai and Abu Dhabi were respectively ranked as the sixth and ninth-best global destinations for medical tourism.

Domestic and international investment

The UAE already has an impressive track record with healthcare investment, having attracted the world-class Cleveland Clinic Abu Dhabi and education programs by NYU Abu Dhabi.

However, founders have plenty of opportunities to attract funding, both from local and foreign investors. Domestic and foreign VCs have raised $0.9B in MENA-specific healthtech-dedicated VC funds since 2020.

More domestic and international VCs are focusing on the region, ready to deploy dry powder. VCs are the main contributors to funding for healthtech startups in the MENA region, with the region primarily dominated by domestic investors. Since 2016, 80% of VC funding has come from domestic investors.

Made in partnership with EMERGE GHI, our latest report provides an overview of the investment landscape of the healthcare industry in the MENA region, excluding Israel.

The growing value of MENA’s healthtech Healthtech in the MENA region is the vertical that has grown the most by combined enterprise value since 2016. The healthtech startup ecosystem in the MENA region is now worth over $1.5B, a 22x increase since 2016.

Healthtech startups in the region are taking off, with more than $200M in VC funding received since 2016.

te of Healthtech MENA region

10

Download the exclusive market intelligence report

Gulf Cooperation Council (GCC) governments

There is an increasing demand for telemedicine in the region, along with the adoption of remote monitoring solutions. Virtual care goes beyond telemedicine and is a game changer for prevention and proactive care.

Countries in the GCC have made significant investments in healthcare and telemedicine, leading the way in the MENA region.

Since 2020, telemedicine service providers in medical centers and hospitals in the UAE have started to offer a 360-degree solution using the help of a regulationcompliant health information system, supporting patients living in remotely built areas.

There are more opportunities for healthtech startups as GCC countries invest in upgrading healthcare. Between 2010 and 2020, the GCC region had the highest healthcare infrastructure investments. Most VC investment activity and value creation has predominantly been focused on startups improving the patient experience, such as digital care and remote monitoring.

Beyond telehealth – other MENA segments Telemedicine leads in terms of VC investment, value and startup creation in the MENA region, but other patientfocused segments are emerging too. Beyond telehealth, VC investment is also active in clinical decision support, practice management and remote monitoring. While most VC investment activity and value creation has predominantly been in the engagement layer: improving patient experience.

EMERGE GHI 2022

11

DEALROOM REPORT

High demand for telehealth

LAUNCHPAD

HEALTH-TECH INNOVATORS HUB

emergeghi.com EMERGE GHI 2022

13

INNOVATORS INNOVATORS

Body fat changes predict cancer therapy outcomes. Today, these changes are invisible. Adiposs is developing a disruptive product that makes body fat changes visible with a simple and fast medical scan. This leads to better patient stratification for oncology drug development programmes and clinical practice. Adiposs has developed ImageBAT, a first-in-class medical imaging product for brown adipose tissue. ImageBAT-enhanced CT scans are fast and painfree and will be available in hospitals globally. The vision and mission of Adiposs is to make ImageBAT-enhanced medical scans available to every cancer patient worldwide, giving them better and longer life.

BioSapien is a biotech company focused on developing a 3D printed drug delivery platform to provide FDA-approved drugs locally, avoiding negative systemic effects. BioSapien is the inventor of the MediChip®, a novel 3D printed biodegradable mesh that delivers drugs in a localised sustained manner for cancer indications with reduced systemic side effects. MediChip’s flexible nature targets mostly the tumor cells and the hard-to-reach tumor sites by delivering the cancer drugs (FDA approved APIs; gemcitabine and 5-FU[FOLFIRI]) directly to the site of the tumor.

Neuroscience company Braingrade is developing a brain-computer interface. The next-level deep brain stimulation device gives direct access to the human brain and improves cognitive abilities. Braingrade’s team of founders and executives from top neurotech companies around the world are working with a team of memory enhancement researchers, neurosurgeons, and neurologists, to develop this new solution firstly for patients with Alzheimer’s disease, allowing them to live longer, independent, lives.

Gendius uses artificial intelligence to measure and improve outcomes for patients with diabetes.

Our solutions are made in collaboration with patients and healthcare professionals, so that we truly understand their needs. We then use our experience from the pharmaceutical industry to test our solutions so that we know they improve outcomes. Intellin is our new app-based platform that helps you live with diabetes. For the first time you can have a personalised assistant that helps you make good decisions every day. It can connect to over 150 apps and devices, simplifying diabetes management and identifying risks of future complications.

14

INNOVATORS INNOVATORS

Integratize.io is disrupting the landscape of clinical trial onboarding through innovative technology. Most clinical trials are done in western Europe and America with very little access to clinical trials in the Middle East, Asia and Africa.

With data being siloed and inaccessible, many people are suffering due to lack of access to clinical trials for new medications. Integratize.io, with its proprietary AI, anonymises the data and allows for ease of onboarding for clinical trials. We speed up and reduce the cost of clinical trials by providing an unparalleled network of patients for trial onboarding. Through our unique network of hospitals and sites, we provide a real-time searchable network, increasing access to life-changing medication. medIQ is working to disrupt the traditional brick & mortar healthcare industry and provide efficient, customised, on-demand healthcare through technology. As Pakistan’s first integrated virtual healthcare platform, medIQ provides everything that companies need to deliver virtual healthcare. This includes a plug-and-play customisable technology stack, a comprehensive network of health service providers, end-to-end support by medIQ’s experts with patient data stored in a HIPPA-compliant Electronic Medical Record system. medIQ is the first solo woman-founded startup in Pakistan which has raised pre-seed funding of US$1.8 million and is currently raising seed-stage funding.

MedJacket brings portable tele-integrated point-of-care testing equipment that amalgamates the versatility of multiple full-scale monitoring equipment. This mobile unit is specialised to monitor, relay and synchronise vital stats in real-time.

Bringing easy portability with accurate, reliable diagnostic and monitoring features, MedJacket aims to revolutionise patient care. This state-of-the-art system combines cutting-edge technology and innovation to deliver reliable point of care testing. With a dedicated, custom interface and connectivity across essential monitoring devices, MedJacket is your one-stop solution for healthcare. MedJacket is designed to fit right in everywhere - from multi-speciality hospitals to primary healthcare centres, homes, ambulances, and even schools and public transport facilities.

MyEngene started with a vision to truly personalise medicine. Our mission is to create a positive healthcare experience by elevating the standard of care that patients deserve and reduce adverse drug reactions (ADR). Our software platform helps patients gain peace of mind when it comes to their health, based on their genetic makeup. MyEngene uses a combination of automation through artificial intelligence, machine learning, and the latest science to give everyday people actionable data derived from their genetic profiles. This information includes genetic predisposition to disease and, most importantly, provides doctors with reports suggesting optimised drug treatment therapies based on individual genetics.

MyEngene

EMERGE GHI 2022

15

INNOVATORS INNOVATORS

The biggest challenge for sponsors of clinical trials is patient recruitment, but small practices and individual physicians can’t afford the clinical site management burden to participate in trials. Nexus, a full-stack technological platform, can break the vicious circle and enable physicians to help more patients enter the trials. At the core of Nexus lies a financial platform enabling direct instant payouts to physicians and patients, eliminating the last barrier to their participation. We are increasing physician and patient participation in clinical trials by 10 times.

Prosperdtx (Prosper Digital Therapeutics) is a leader in the emerging field of digital therapeutics, proactively delivering targeted support to cancer patients that they may live better lives. We are at the intersection of medical innovation and computational technology to provide high-value support while reducing the cost of care. Prosperdtx is building a preeminent digital therapeutics company that aspires to revolutionise the current cancer care landscape through unique digital therapeutics solutions. We look to improve cancer patient outcomes by replacing the current low-value care with personalised and prospective digital care solutions that deliver high-value outcomes to the patient and patient care stakeholders.

RobotDreams is developing AI-based software for diagnosing cardiovascular diseases based on blood tests. RobotDreams offers a very simple and affordable artificial intelligence solution to the growing global problem of identifying and treating cardiovascular disease. Software integrated into the laboratory will analyse the blood during a routine examination in a few seconds and can very accurately diagnose heart disease, saving valuable time and helping patients receive proper treatment fast. RobotDreams uses AI algorithms to evaluate the blood parameters and output the results in the environment of a laboratory information and management system. The whole process from blood collection to diagnosis can be done within a few minutes.

SanoCRM is a customer relationship management system specifically designed for healthcare organisations, helping them to improve patients’ health and optimise their internal processes. Its main goal is to help retain existing patients and attract new ones. It aggregates different data such as patients’ demographics, interactions with the organisation’s website and call centres, financial and other relevant details to create a comprehensive patient profile. Enriched with data analytics, SanoCRM can point to the patients who could benefit from particular healthcare services or need regular follow-ups. SanoCRM can also contribute to improving internal processes of healthcare organisations, reducing no-show rates and automating resource management.A

16

INNOVATORS INNOVATORS

Scirosbio is a home-grown UAE-based bio-pharmaceutical company that is engaged in research, development and commercialisation of drugs majorly related to ROS (reactive oxygen species) biology for various disease indications, including oncology, neurological disorders, and diabetes. Our proprietary “RAID” technology platform utilises a combination of ROS modulating small molecules synergistically with other standard therapeutics to enhance therapy outcomes. The platform provides wellunderstood active substances with a high safety profile for a rapid clinical development, helping to treat unmet medical needs.

Telebionix is a med-tech innovation company based in California.

Telebionix’s flagship product, Remosense, is the perfect tool for healthcare providers and patients to allow proactive, predictive, and reliable healthcare access to improve and save lives. It is the first fully integrated end-to-end health ecosystem designed specifically to transform the digital health era, powered by artificial intelligence, delivering healthcare providers accurate data, ensuring better health outcomes and a better quality of life for patients and caregivers.

Remosense will free up the bottleneck of the clinician shortage by eliminating unnecessary visits, cutting healthcare costs, and expanding access to quality care for underserved communities.

Omnigene Medical Technologies Ltd is a bio-tech start-up with capacity to provide advisory services in genetic analysis and quality control of multiplex assays based on xMAP technology, and with plans to set up an in vitro diagnostics manufacturing site, providing kits for diagnostic services. Through collaborative efforts with international partners, the company has enhanced its capacity to generate innovative products in the field of oncology, neuroscience and emerging needs, as evidenced by the research project on SARS-CoV-2 (COVID-19) immune response for vaccine surveillance. Our vision is to position ourselves as influencers in the field of patient management, cancer screening programmes and emerging medical needs.

BrainBeat is a therapeutic, at-home training system designed to improve a child’s focus, attention, grades, coordination, behaviour and more. BrainBeat’s specially designed video games guide children through fun and engaging physical and cognitive exercises shown to improve focus, brain synchronisation, memory, and mental speed through real-time, milli-second training and feedback.

BrainBeat is based on research-backed medical technology called Interactive Metronome (IM). IM has been used clinically for more than 20 years by over 40,000 professional clinicians around the world. This powerful brain-body technology is also used to help rehabilitate adults after traumatic brain injuries, strokes, and other neurological diseases.

EMERGE GHI 2022

17

REVOLUTIONARIES SPOTLIGHT

Recognising Healthcare Revolutionaries DR MIN PARK

Dr Min Park has made a measurable impact during his life. He has been a dedicated and generous colleague and a great mentor to everyone around him. He puts forward an in-depth and authentic case to compassionately lead his teams towards understanding the complexity of any situation. He established a positive work environment and taught his team the skills necessary to voice, listen to, and deeply understand each other’s points of view. In all his achievements, he has consistently encouraged others. His dedication and commitment to his work are his most valuable assets.

DR NADIA KHALIL AL SAYEGH

Dr Khalil Al Sayegh has actively participated in establishing the fundamental rules of volunteer work in the UAE across various categories. Her efforts have included supporting university education for families with low incomes, and an initiative to support the religious aspects of people of determination (two Umrahs) in the Year of Giving (2017), two Umrahs in the Year of Zayed (2018), three Umrahs in 2019, and one Umrah in 2020, offering therapeutic support for patients with cancer and kidney failure. She has completed more than 45 specialised training courses in the field of family counselling for people of determination, developing thinking skills in family, physical and psychological treatment, family happiness, and mental health for social workers. Other areas include modern leadership, developing leadership skills, and the role of social workers in dealing with crises, anger, diagnosis and social therapy.

She has served in this field for nearly 36 years and focused, in particular, on the care and rehabilitation of orphans of determination within a 24-hour humanitarian edifice with a specialised medical, therapeutic and academic staff.

UNIVERSITY OF SHARJAH

The University of Sharjah ranked No 1 amongst UAE universities in the publication of Biomedical reports and in Health Science & Genetics from 2020-2021, with 2,287 publications. The university developed the implementation of single cell omics, a technique that allows understanding the mechanisms of various diseases at a very high resolution, identifying pathways and biomarkers for individual patients.

MEDIA KIT

UNIVERSIT Y OF SHARJAH

18

PETER SCHLECHT

Peter is a neuro-tech entrepreneur and the CEO & founder at Braingrade. His goal in life is to provide everyone with a brain upgrade.

With Braingrade, Peter and his team are developing a brain-computer interface.

The next-level deep brain stimulation device gives direct access to our brains and improves our cognitive abilities. It will first be helping millions of Alzheimer’s patients.

After exiting his AI company, Peter founded Artificial Link and the neuroscience company Braingrade.

Besides running Braingrade, he supports as a mentor Singularity University, Singa, Startupbootcamp, Betahouse, and the Founder Institute. His charitable activities include Bitkom, Wirtschaftsrat, Mensa, Sandbox & Founders Pledge.

DR BURHAN FAKHURJI

Dr Burhan is the founder of the iGene Medical Research & Training Center located in Kingdom of Saudi Arabia. The award-winning centre provides specialised medical training courses and outstanding workshops that enhance practical skills. It is considered the first innovative centre in the private sector in the KSA, founded by a highly skilled team, which consists of genomic scientists and consultants with expertise in multiple areas. Its efforts include raising the level of scientific research skills in the field of molecular genetics and cancer cell diseases, by providing stateof-the-art medical technology laboratories which have attained Bio Safety Level 2 plus (BSL2+). Its goal is to make ideas a reality and find the perfect solutions to diseases that are widely spread. The iGene registry is a Saudi Commercial Innovation System that provides a unique innovation service including consultation, training and assistance to innovators in creating their innovation prototypes in the field of molecular technology.

EMERGE GHI 2022

19

SPOTLIGHT

REVOLUTIONARIES

Co-located with

24-25 MAY 2022 CONRAD DUBAI

DOWNLOAD THE BRELLA APP AND NETWORK WITH INDUSTRY LEADERS. THE ONLY DEDICATED PRECISION MEDICINE EVENT IN THE MIDDLE EAST Book Meetings

DOWNLOAD THE BRELLA APP

12

Browse Exhibitor & Products

View Speakers & Agenda